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ROLE OF NUDT+, MEDIATED ALTERNATIVE POLYADENYLATION AND
HYALURONAN IN THE DEVELOPMENT OF PULMONARY HYPERTENSION
Abstract
Scott Dale Collum
Advisory Professor: Harry Karmouty-Quintana Ph.D.

Pulmonary hypertension (PH) is a progressive disease with serious
effects on quality of life and life expectancy of patients. PH is a complex
disease that likely develops due to multiple influences, and no curative
treatments exist for this disease. It has been shown that alternative
polyadenylation (APA) due to depletion of Nudix Hydrolase +,(NUDT+,) is
involved in several disease states including the chronic lung disease idiopathic
pulmonary fibrosis (IPF). Additionally, hyaluronan, an extracellular matrix
glycosaminoglycan has been associated with PH. The role and mechanism of
NUDT+, and hyaluronan have not yet been described in this disease. My
results reveal that NUDT+, depletion and APA in pulmonary artery smooth
muscle cells (PASMCs) is associated with phenotypic changes and PH. I I also
show that hyaluronan and hyaluronan related genes play important roles in
the development of Pulmonary Arterial Hypertension (PAH) and PH
associated with IPF and combined pulmonary fibrosis and emphysema. I also
identify f-methylumbelliferone as an inhibitor of PH in this mechanism. These
studies provide new mechanisms for understanding the development of PH
and potential therapeutic targets.
vi
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Chapter 1: Introduction

A portion of this chapter, including figure 1 is adapted from a review published
in the Canadian Respiratory Journal. Collum SD, Amione-Guerra J, Cruz-Solbes AS,
DiFrancesco A, Hernandez AM, Hanmandlu A, Youker K, Guha A, Karmouty-Quintana
H. Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current
and Future Perspectives. Can Respir J 2017

Pulmonary hypertension (PH) is a disorder of the lung vasculature. Clinically,
PH is defined by an increase in mean pulmonary arterial pressure (mPAP) over 25
mmHg accompanied by a pulmonary artery wedge pressure under 15 mmHg and an
elevated pulmonary vascular resistance (1). Physiologically PH includes remodeling and
thickening of the pulmonary vasculature walls and a subsequent loss of luminal spaces.
This loss of lumen and increase in pulmonary pressures cause an increased load on the
right ventricle (RV). As the RV compensates aberrant remodeling occurs in the RV wall
leading to hypertrophy and death by right-sided heart failure. The World Health
Organization (WHO) classifies PH into five groups based on primary clinical diagnosis
and histopathology (2). This study focused on two of the classifications; Group 1 or
pulmonary arterial hypertension (PAH) which is not associated with other cardiopulmonary diagnosis and Group 3 or PH due to lung diseases including interstitial lung
diseases such as idiopathic pulmonary fibrosis (IPF) or chronic obstructive pulmonary
disease (COPD).

1

Group 1 PH
Group 1 PH includes several diagnostic groups; heritable pulmonary arterial
hypertension, drug and toxin-induced PH, PH associated with connective tissue
diseases devoid of lung involvement- and congenital heart disease associated PH. Total
annual prevalence of Group 1 PH is estimated to be 40-127 cases per 100,000 in large
cohort studies (3-5). Five-year survival rates are 69.4% after initial diagnosis (3). This
classification group contains 69.9% females with a mean age of 50 years old (5). While
there are no curative treatments for Group 1 PH, several drugs may increase survival
time and quality of life in patients. The most common drugs are endothelin receptor
antagonists, drugs targeting the nitric oxide pathway such as phosphodiesterase type 5
(PDE-5) inhibitors or soluble guanylate cyclase activators, and prostanoids used as
vasodilators (6-8). These treatments are given as monotherapies or in combination as
the patient progresses (9). While strides have been made and these drugs may increase
3 year survival rates by up to 70% in some cohorts this disease is still progressive and
lung transplantation or death is the final outcome (10). In heritable cases of Group 1 PH
a mutation of bone morphogenic protein receptor 2(BMPR2) is found in about 80% of
cases while an additional 5% of cases are associated with other members of the
transforming growth factor 𝛽 signaling pathway (11, 12). Many rare mutations are also
associated with this heritable disease including mutations in caveolin-1 and activinglike receptor kinase 1. Group 1 PH often presents with more severe pulmonary pressure
changes and plexiform lesions than other classifications of pulmonary hypertension (1).
Plexiform lesions are vascular structures of the pulmonary artery that are formed of
proliferative and potentially phenotypically distinct endothelial cells, myofibroblasts
2

and smooth muscle cells (13).

Group 2 PH
Group 2 is PH developed due to left heart disease. The prevalence of this group
is the highest of the 5 WHO classifications as heart failure is one of the largest public
health emergencies with over 23 million cases worldwide (14). It is difficult to establish
the exact number of these patients that develop PH as it is often a consequence of
progression in heart failure. The pathophysiology of the development of Group 2 PH is
unique in that it begins as a mechanical stress due to increased pulmonary venous
pressures due to the left heart dysfunction (15). This stress then causes damage to the
pulmonary vasculature and only then do I see similar remodeling and vasoconstrictions
to other forms of PH and eventual right heart changes (16).

Group 3 PH
Group 3 PH is associated with chronic lung diseases such as IPF and COPD but
it also a result of chronic hypoxia, such as that encountered in high altitude
environments (1). Overall Group 3 PH is more common than Group 1 PH, true incidence
though must be looked at in conjunction with the associated primary chronic lung
disease (17). Diagnosis of increased pulmonary artery pressures in patients with chronic
lung disease is difficult as right heart catheterization is quite invasive and
echocardiography is not as sensitive even with recent advances (18). The prevalence of
IPF is estimate to be 14-43 per 100,000 while the prevalence of PH amongst IPF patients

3

is dependent upon the severity of IPF. In the early stages or when initially diagnosed,
PH aﬀects < 10% of IPF patients. However, as IPF advances, the incidence of PH
increases markedly. One study of patients awaiting lung transplant, and thus in an
advanced stage of IPF, reported prevalence of 32%. Subsequent studies have largely
supported or increased this percentage to be between 32 and 50%. However, it is
important to mention that the symptoms for PH and IPF are very similar (shortness of
breath and exertional dyspnea) and as such it is conceivable for PH to be
underdiagnosed in patients with IPF. Furthermore, typically the mPAP of patients with
IPF is significantly lower than patients with Group 1 PH. Despite this, the presence of
PH in IPF is strongly linked to the increased mortality and eﬀorts aimed at treating PH
in IPF may provide much needed therapies to diminish the mortality of IPF. IPF is a
disease for which there is no curative treatment outside of transplantation, thus out of
proportion PH, which disqualifies patients from transplants, is a serious confounding
factor (19). The treatment options seen in Group 1 PH have not proven to be successful
in Group 3 PH or have had adverse clinical outcomes (20, 21). This and the strong
mortality link make understanding the mechanism of PH development critical to
treating patients with a diagnosis of chronic lung disease.
COPD prevalence is much higher than IPF at 7.6% of the population (22). Similar
to IPF the prevalence of PH associated with COPD is dependent on the severity of
COPD. In early stage COPD as few as 10% of patients may have increased pulmonary
pressures (18). In patients awaiting surgical intervention and thus having severe COPD
the rates may be near 90% (23). Patients with PH associated with COPD have almost
50% increase in 5-year mortality rate (24). Five-year survival rates for Group 3 PH after
4

initial diagnosis are 41.4% but the identity and severity of the underlying lung disease
obviously has large impacts here (3).
An additional chronic lung disease that is associated with PH is combined
pulmonary fibrosis and emphysema (CPFE). This relatively recently defined disease has
fibrotic deposition associated with emphysematic destruction of alveoli (25). Alone
CPFE has a 5 year survival rate of 55% but when associated with PH 1 year survival rates
may be as low as 60% (26). Additionally, up to 90% of CPFE patients will develop PH.
As this disease has what on the surface appear to be countervailing mechanisms of
fibrotic deposition and destruction of alveoli, it is important to discover the molecular
mechanisms that can contribute to both events. While there have been multiple gene
mutations associated with CPFE these mutations have not yet been shown to be
widespread, as their discovery was part of familial cohorts or case studies (27).
Unfortunately, treatment of CPFE or Group 3 PH overall, is limited to controlling
symptoms and lung transplantation (28).
A more distinct form of Group 3 PH is associated with hypoxia at high-altitude.
This type of PH can both be acute and chronic (29). In acute high-altitude PH patients
can develop increased pulmonary pressures very quickly due to an excessive
vasoconstriction caused by hypoxia (30). In fact, acclimatization does not appear to
reduce increases in pressure but does reduce symptoms, potentially by subtle
remodeling of the vasculature to better protect from increased pressures (31).
Additionally, changes seen in this group are reversible by returning to low altitudes.
Chronic high-altitude pulmonary hypertension is a threat to the more than 140 million
people living above 2,500 m elevation. It is estimated that in these populations 5-18% of
5

residents will develop high altitude PH (32). Healthy residents at high altitude have
thickened pulmonary artery walls that may form before birth (33, 34). This remodeling
is not the key driver for this PH as even in chronic cases aberrant vasoconstriction
appears to be the most important mechanism of increased pressure. Patient with this
disease are encouraged to move to low altitude which will manage the disease but many
pharmacological interventions have shown promise with none moving to widespread
use. Most promising are experiments with fasudil as well as acetazolamide, a carbonic
anhydrase inhibitor, which has several larger studies with excellent results (35, 36).

Group 4 PH
Group 4 PH is PH developed due to a chronic thromboembolic disease. Patients
that develop a pulmonary embolism, especially those with coagulation disorders or
autoimmune disease, are at risk though less than 4% of these patients will develop the
chronic disease (37, 38). An unresolved pulmonary embolism causes occlusion of
pulmonary vessels causing increased localized pressures and shear stress. This in turn
results in remodeling of the affected vessels (38). As this is most often confined to one
section of the lung, surgical intervention to remove the blocked vessel is often effective
(39).

Group 5 PH
Group 5 PH is PH with unclear multifactorial mechanisms. This classification is
a catchall for PH that is associated with disease states not incorporated in the other
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groups (2). As this is a diverse group little research links the mechanism of this group.
The most well described disease associate with Group 5 PH is sickle cell disease which
can lead to PH due to left ventricle dysfunction or vascular stress caused by hemolysis,
embolisms or hypoxia (40).
Though the exact number of patients affected by all classifications of PH are hard
to calculate, the patients impacted by these diseases have severely reduced quality of
life and have much lower life expectancy. With the rise in cases of chronic lung disease
in recent decades and the lack of treatment options, it is important to thoroughly
understand the molecular and cellular mechanisms that underpin how PH develops.
Only by this understanding can novel treatment options be explored.

Disease Mechanism
The primary mechanisms involved in the increase of pulmonary vascular
pressures in PH are increased vasoconstriction and sustained vascular remodeling.
Many cell types have been shown to be involved in the development and progression of
PH including pulmonary artery endothelial cells, fibroblasts, and immune cells such as
macrophages. Vascular endothelial cells are the inner most cells of the pulmonary
vasculature, as such they are often the first cells damaged by stress events that initiate
remodeling seen in PH. Endothelial cells also have strong signaling connections with
pulmonary artery smooth muscle cells (PASMCs) through endothelin-1 and nitric oxide
signaling as well as many growth factors (41, 42). Vascular inflammation is a key
characteristic of PH and as such macrophages have been implicated in multiple roles
during the development of PH (43). Blocking macrophage activity or development has
7

shown efficacy in halting or reversing PH in some model (44, 45).
PASMCs are very involved in both vasoconstriction and vascular remodeling.
This makes PASMCs an exciting target for research hoping to understand the
underlying molecular mechanisms that contribute to PH. While PASMCs of the
proximal pulmonary arteries have a heterogeneous phenotype the cells of the distal
pulmonary arteries, which are more involved in PH development, have a more uniform
phenotype (46, 47). These PASMCs have a well differentiated phenotype that expresses
many factors indicative of a contractile capacity and a low proliferative potential. These
cells are key in modulating vascular tone that allows for control of pulmonary artery
pressure and changes in flow rate seen during periods of activity (48). In a healthy
pulmonary artery, there are three regions when viewed cross-sectionally. The inner
layer is the intima comprised of pulmonary artery endothelial cells. Next is the medial
layer of PASMCs and finally the adventitial layer which signals the transition to other
lung structures, is comprised of other cell types including fibroblasts. In a PH artery,
the intima may be infiltrated by smooth muscle cells, the medial smooth muscle cells
will proliferate and hypertrophy while the adventitial layer will have increase in
fibroblasts and macrophage infiltration (40). These changes contribute to the main
pathological signs of PH, medial hypertrophy leading to reduced lumen in previously
muscular arteries and increased abundance of muscular arteries due to muscularization
of peripheral arteries and potentially plexiform lesions (1).
PASMCs undergo many phenotypic changes during the initiation and
development of PH. Early in the development it has been shown by many experimental
models that there is an increase in proliferation. This was first seen in the rat hypoxia
8

model in which there was a small amount of medial PASMC proliferation increase and
confirmed in the monocrotaline rat model where there was observed a more robust
increase in proliferation (49, 50). The hypoxia model of rat pulmonary hypertension
treats the rats with 14 days of hypobaric hypoxia (49). In the monocrotaline model rats
are treated with a single dose of monocrotaline which causes pneumotoxicity. After 14
days the pulmonary arteries are very inflamed and PASMCs are contracted and by day
22 there are right ventricle dysfunctions (51). Of interest is that despite the differences
in these two models in showing a change in medial PASMC proliferation both models
show a very significant increase in the number of muscularized vessels indicating not
just a concentric increase in PASMC but also spreading of these cells to more distal
portions of the arteries (52). As more models of PH have been developed, these changes
in proliferation have been more precisely studied. More recent studies have confirmed
the early increase in proliferation seen but indicate that this proliferative capacity
decreases as the model continues and the cells potentially progress into a second
phenotype change (53). This has been observed in the mouse Schistosomiasis model
and in one of the more utilized models of PAH, the hypoxia-sugen rat model (53, 54).
The Schistosomiasis model involves inoculating mice with Schistosoma mansoni and
then a second hit with i.v. administration of S. mansoni eggs. Seven days after
administration of the eggs, PH develops in an IL-13 dependent mechanism (54). The
hypoxia-sugen model treats mice with 28 days of 10% oxygen and four treatments with
a vascular endothelial growth factor inhibitor leads to increased pulmonary pressures
and remodeling (55). PASMC proliferation provides for the medial thickening seen in
the development of PH and provides an increased pool of PASMCs to participate in the
9

other abnormal phenotypes that are introduced below.
Another phenotypic change seen in PASMCs during the development of PH is
an increase in cellular tone. During exercise the cardiac output of the right ventricle will
increase to provide for more oxygen delivery (56). To minimize the increase in
pulmonary artery pressure due to this increase in right heart effort the pulmonary
arteries relax, allowing for a reduction in pulmonary vascular resistance. In fact, in a
multi-study analysis it was seen that the slope of the relationship between mPAP and
cardiac output in an individual can vary by as much as 6 fold when a stable linear
relationship would be seen in a non-contractile system (57). If this relaxation does not
occur then pulmonary pressures will increase as seen in PH. As with many other key
cellular signaling events, Ca2+ activated response controls the contractility of PASMCs
(58). Since Ca2+ signaling has other outputs, many studies have worked to understand
the signaling necessary for the contractile response in PASMCs. A key phosphorylation
event is the phosphorylation of myosin regulatory light chain (59). The levels of this
phosphorylation are controlled by the interplay of calcium-calmodulin dependent
myosin light chain kinase and the MLC phosphatase (60). PASMC contractility is not
controlled by a change in Ca2+ but by a calcium sensitization caused by the Rho-kinase
(ROCK) dependent phosphorylation of myosin targeting phosphatase subunit (60).
ROCK is previously activated by Ras-homology A(Rho) in its GTP bound state (60). This
sensitization ends when regulatory proteins cause RhoA to cleave GTP (61). These
proteins and the nucleotide exchange factors are under tight control, allowing for
multiple upstream pathways to control PASMC contractility (62). As there are many
signaling pathways controlling PASMC contractility it is of no surprise that in PH many
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pathways and signaling mechanisms can lead to increased vascular tone. One of the
mediators involved is endothelin. Endothelin-1 is released from pulmonary artery
endothelial cells due to stress and signals through the Endothelin receptor B (63). This
signaling leads to Ca++ dependent signaling changes through IP3 (64). This complex
control of contractile response in PASMCs allows for fine tuning of the vascular
resistance in healthy individuals and maintains a suitable pulmonary artery pressure
but allows for changes in signaling in a disparate set of pathways to abnormally control
this contraction in the development of PH.
An additional change seen in PASMCs is an increase in the production of
extracellular matrix (ECM). The ECM is a combination of proteins and polysaccharides
surrounding the cells of every tissue. The exact make up of ECM in each tissue varies
and ECM is dynamically produced and degraded (65). The ECM does not only provide
a structural lattice for cellular components of tissues but also plays an important role in
signaling many cellular activities including proliferation, migration and cellular
distribution through interactions with many signals including growth factors (66). The
main protein component of all tissue and of the ECM is collagen, a protein whose many
functions and interactions are only rivaled by the many classifications and variants
expressed. Collagen provides tensile strength, cell interactions, migration and tissue
polarization cues. A second ECM protein is elastin, a highly crosslinked protein that
helps provide stretch and recoil to tissues. The third major protein in ECM is, in concert
with collage, which is very important in the development and presentation of many
chronic lung diseases including PH and IPF is fibronectin (FN). FN has been implicated
in a feedback loop that keeps PASMCs in a synthetic phenotype with increased
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proliferation (67, 68). The other molecule type that composes a large portion of the
ECM are glycosaminoglycans. These polysaccharides are usually found covalently
bound to a variety of ECM proteins and provide interactions and help provide a strong
and hydrated matrix (69). These proteoglycans often are helper proteins in cell surface
receptors (70). One exception to extracellular glycosaminoglycans being covalently
bound to proteins is hyaluronan (HA). This molecule instead binds to many ECM
proteins and cell surface receptors such as CD44 through specific binding motifs called
Link domains, though as the catalogue of HA binding proteins expands some lack this
domain (71). This molecule will be further introduced later in the thesis. During the
development of PH, a population of PASMCs may switch into a synthetic phenotype
which can deposit these ECM components. This deposition allows for multiple effects.
The modified ECM can feedback into the PASMCs maintaining an abnormal phenotype
(67). The new ECM can provide a foundation for cell adhesion and immune cell
infiltration into the vasculature (72). Finally, the excessive ECM can cause mechanical
stiffening to the pulmonary vasculature and physical block to gas exchange (73).
Together these PASMC dependent ECM changes contribute to many of the other
phenotypic changes seen in the development of PH and provide an important research
subject.
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Figure 1 Vascular Remodeling
Adapted from Pulmonary Hypertension Associated with Idiopathic Pulmonary
Fibrosis: Collum SD, Amione-Guerra J, Cruz-Solbes AS, DiFrancesco A, Hernandez
AM, Hanmandlu A, Youker K, Guha A, Karmouty-Quintana H. Pulmonary
Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future
Perspectives. Can Respir J 2017
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Chapter 2: Background

RNA Processing
Transcription of protein coding mRNAs by RNA polymerase II is the first step in
turning genetic information in the DNA of cells into molecules that can maintain the
homeostasis of the cells, decide cell fate, and provide the functional capacity for this
fate. It is not surprising then that transcription is a process involving many steps each
of which is complex and must be tightly regulated. To properly discuss the final step in
transcription, cleavage and polyadenylation, it is useful to briefly discuss the
transcriptional processes that precedes it. The basic structure of a viable, stable and
translatable mRNA is to contain a 5’ m7G cap, a 5’ untranslated region (UTR), the coding
sequences containing a start codon and a final stop codon, a 3’ UTR and finally a poly(A)
tail of many adenosine monophosphates.
The first step of transcription is initiation. During this process five general
transcription factors assemble with RNA pol II to form the preinitiation complex. This
complex recognizes the DNA regions that most eukaryotic RNA pol II genes contain
called the TATA-box and the TFIIB recognition element. These sites are about 30 bases
upstream of the transcription start site and allow for proper positioning of the
transcription complex. This site recognition can be modified by transcription cofactors
and enhancer regions and the proteins that bind them called activators and repressors.
Control of transcription initiation is provided by large protein complexes interacting
with each other and DNA over 100 Mb away (74). After initiation of a stable complex
the RNA pol II begins elongation adding nucleotides sequentially to the 3’ of the nascent
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mRNA. After 25-30 nucleotides the capping enzyme is recruited by a phosphorylated
serine on the RNA pol II and carries out three enzymatic steps to cap the mRNA. The
final step in this cap addition, the methylation by RNA guanine-N7 MTase can be also
controlled in a cell cycle manner by CDK1-cyclin BI (75). Another co-transcriptional
mRNA processing event that begins during elongation is splicing. Similar to the
recruitment of the capping enzyme by RNA pol II the spliceosome, a large complex of
proteins and small nuclear ribonucleoproteins, is recruited by a C-terminal domain
phosphorylation (76, 77). The spliceosome then recognizes splice sites within the premRNA and removes intervening sequences that do not form a portion of the mature
RNA (78). Splicing was discovered to not be a constitutive process but to have many
variations and controls. In fact alternative splicing has helped to explain the disconnect
between the number of putative genes and mature proteins that are produced, as it has
been discovered that at least 70% of human genes undergo alternative splicing in tissue
or developmental regulated manner (79). It is also calculated that up to 60% of human
heritable diseases involve a splicing change due to mutation (80). Splicing provides yet
another process to control mRNA processing. The final step in transcription and
maturation of RNA pol II mRNAs is cleavage and polyadenylation. This process involves
the recognition and enzymatic cleavage of a cleavage site and then the addition of a
poly(A) tail, this is known as cleavage and polyadenylation.

Cleavage and polyadenylation

Cleavage and polyadenylation is carried out at a location of the pre-mRNA
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defined by a set of sequence signals of which are relatively well conserved with potential
activity with major mutations and a set of more diffuse and weaker signals that stabilize
the more conserved signals (81). These signals do vary by species so here is described
the signal elements for mammals. The first and strongest signal is a hexamer sequence
AAUAAA just upstream of the cleavage site. Other similar hexamers have much reduced
processing activity while AUUAAA and AGUAAA retain 80% and 30% respectively (82).
The first synthetic poly(A) site consisted of this hexamer and a U/GU rich sequence 22
nucleotides downstream (83). Besides these strong signals there is an U-rich region
within 100 nucleotides upstream and downstream as well as potential G-rich elements
more than 30 nucleotides downstream (84). The RNA sequence UGUAN can also act as
a strong promotor of cleavage and polyadenylation and is often found upstream of the
PAS (85). Cleavage and polyadenylation is carried out by a protein complex that is
known to have greater than 80 associated factors. Of these associated factors 19 proteins
make up the core of the machinery (86). The cleavage and polyadenylation specificity
factor (CPSF) is a sub-complex made of six required proteins; WDR33, CPSF30, CPSF160,
hFip1, CPSF100, and CPSF73. WDR33 is the protein that binds the AAUAAA hexamer
while CPSF30 and CPSF160 assist in this recognition and binding (87, 88). While both
CPSF100 and CPSF73 contain metallo-β-lactamase and 𝛽-CASP domains it is CPSF73
that cleaves pre-mRNAs (89). The CstF complex is a trimeric complex that recognizes
downstream elements in the PAS. It consists of CstF64, CstF77, and CstF50 (90).
Together these proteins recognize U/GU rich regions as well as modulating some
protein interactions outside the cleavage and polyadenylation machinery (91, 92).
Symplekin is a protein that acts as a scaffold for the arrangement of several of the
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subcomplexs of the larger cleavage and polyadenylation complex (93). The mammalian
cleavage factor I is made of 3 proteins, Nudix Hydrolase 21 (NUDT21), CPSF6 with two
splicing isoforms, and CPSF7 (94). NUDT21 binds the UGUAN while forming a dimer
with itself and potentially a tetramer with a dimer of one of its complex partners (94).
When in this tetramer with CPSF6 it is known that this binding to RNA can cause a
looping which is theorized to be important in recognition of a proper cleavage and
polyadenylation site and alternative polyadenylation (APA) (95, 96). The mammalian
cleavage factor II complex contains up to 20 proteins but only (Cleavage and
Polyadenylation Factor Subunit 1 (Clp1) and Pcf11 have been well characterized. Clp1
appears to assist in the assembly of CFIm and CPSF while Pcf11 is essential for
degradation of the remaining nascent RNA after cleavage (97, 98). The final proteins
considered part of the core cleavage and polyadenylation machinery are Poly(A)
Polymerase Alpha (PAP) and Poly(A) Binding Protein Nuclear 1 (PAPBN1) which add
the poly(A) tail. PAP catalyzes the reaction adding adenosines in a templateindependent manner while PABPN1 binds the tail as it is added and increases the
catalytic rate of PAP (99, 100). Additionally the C-terminal domain of the RNA pol II is
again key in recruiting the factors discussed here (101).

Alternative Polyadenylation
Alternative polyadenylation is a process in which an pre-mRNA with multiple
poly(A) signals may use a non-canonical site. While this mechanism of regulating
mRNAs was first proposed and discovered in a few specific cases in the 1980s, amongst
others the IgM heavy chain and dihydrofolate reductase, it was not until more
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sophisticated techniques in the modulation of protein levels and RNA quantification
were developed that the true scope of this process could be recognized (102, 103). With
the advent of next generation RNA sequencing technology the ability to identify APA
events as a result of many diseases or manipulated protein levels showed that at least
69.1% of human genes have multiple poly(A) sites (104). There are four basic types of
APA as grouped by the location of the non-canonical poly(A) site. The first and most
easy to visualize is tandem 3’UTR APA which occurs when there are additional poly(A)
sites within a single 3’UTR. Tandem 3’UTR APA is the only type which generates an
identical protein coding sequence and thus this form of APA has a more difficult effect
to study (105). Alternative terminal exon APA creates a new terminal exon and 3’UTR
while intronic APA is similar but also retains a canonically spliced intron (105). Finally
is internal exon APA which maintains the typical splicing pattern but cleavage
recognizes a typically ignored sequence within one exon which is the most rare of APA
events (106). The rest of this thesis will focus on Tandem 3’UTR APA as while this type
does not affect the coding sequences changes in the 3’UTR length can affect the stability,
translation efficiency, and cellular localization of mRNAs through loss of miRNA
binding sites and RNA binding protein sites (Figure 2). These changes will affect
signaling, disease processes, and development.
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Figure 2 3’UTR APA

Regulation of APA
As can be seen by the large number of complexes that interact during
transcription and cleavage and polyadenylation, it is not surprising that many factors
can modulate the occurrence of APA events. APA can be controlled by simple kinetics
of transcription where pausing increases nearby poly(A) site usage (107). Additionally
the efficient recruitment of cleavage and polyadenylation complex by RNA pol II and
transcriptional activating proteins early in transcription can influence poly(A) site usage
(85). Many RNA binding proteins also regulate APA events. Two examples are SR
proteins Serine and Arginine Rich Splicing Factor 3 (SRSF3) and Serine and Arginine
Rich Splicing Factor 7(SRSF7) were first discovered to regulate splicing but have also
been observed to lengthen and shorten 3’UTRs of mouse cells (108). Splicing is also
linked to the control of APA. To avoid premature cleavage and polyadenylation U1
snRNP inhibits poly(A) site usage in introns in a process termed telescripting (109).
Telescripting may also play a role in APA of genes during periods of transcriptional
upregulation (110). Of great interest is the effect of the cleavage and polyadenylation
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complex levels on APA. Changes in the levels of each of the core components appear to
have different effects. Increases in CSTF64 was seen to increase CSTF complex and
increased the usage of a proximal poly(A) while downregulation of expression leads to
global lengthening in HeLa cells (102, 111). This suggests that the CstF complex may
follow this trend.
In stark contrast to APA changes seen by modulating levels of CSTF64, down
regulation of CFIm complex members leads to a strong shortening on a global level (112).
Of note the most robust 3’UTR shortening seen is with the knockdown of NUDT21 (113).
This change has now been seen to play a role in multiple disease states.

NUDT21 Regulated APA and Disease
As the role of CFIm complex members in controlling APA was being discovered,
multiple diseases were found in which levels of NUDT21 were modified as was global
poly(A) site usage. One of the first studies that linked NUDT21 to a disease was by
Masamha et al. which described the role of CFIm25 (NUDT21) in glioblastoma tumor
suppression (113). In this paper it was described that in cell culture human glioblastoma
cells had lower levels of NUDT21 and that this directly contributed to a more
proliferative phenotype as well as a more aggressive tumor in a xenograft mouse tumor
model. This study also identified 1450 genes that underwent APA with NUDT21
knockdown. An additional disease in which NUDT21 was found to play a role was
pulmonary fibrosis (114). In this study by Weng et al. reduced NUDT21 induces APA in
many genes in lung fibroblast and leads to worsening fibrosis in the bleomycin mouse
model. Additionally, a knockout of NUDT21 contributed to increased expression of
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collagen fibronectin and TGF-βR1. APA induced by NUDT21 level changes has been
implemented in many changes in other cancers including hepatocellular carcinoma in
which cellular migration and invasion are increased with depleted level as well as in
osteosarcoma in which similar changes are seen (115, 116). NUDT21 copy number
changes also play a role in the neuropsychiatric disease Rett syndrome by controlling
levels of the protein MeCP2 (117).
NUDT21 regulated APA has been shown to play a role in several diseases
including the chronic lung disease IPF. This APA is also associated with changes in cell
proliferation and cell migration as seen in the study on glioblastoma. These changes in
cell phenotype may resemble changes seen during the initiation and development of
PH and provide a unique opportunity to discover a mechanism of disease progression.
This thesiswill describe a role for NUDT21 in PH.

Hyaluronan
Hyaluronan is a non-protein component of the ECM with a repeating
disaccharide structure of N-acetyl-glucosamine and glucuronic acid. HA is produced in
mammals by three hyaluronan synthases (HAS), 1-3. These synthases produce HA in a
broad range of molecular weights, generally above 2x105 Da with HAS2 generally
producing at molecular weights an order of magnitude higher than the other enzymes.
HAS2 is an essential gene for mouse embryonic development but a double knockout of
the other enzymes is viable with abnormal wound healing. Offsetting these HA
producing enzymes are four hyaluronidase isoforms (Hyal1-4). Of these, Hyal2 has
shown to be the most necessary with deficient mice accumulating HA in the heart and
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developing severe cardiac phenotypes (118). Hyal1 and Hyal3 deficient mice show minor
changes in skin dendritic cells and alveolar structure respectively (119). While some of
the effects may seem minor, Hyal are quite important as in humans one third total HA
is turned over each day, either absorbed by cells by endocytosis or cleared from the
blood by liver endothelial cells (120). HA can also be degraded in an uncontrolled
manner by reactive oxygen species (121). As with other ECM components, HA is bound
by many proteins including proteoglycans. This forms a complex mesh that may play a
role in organizing activities and signaling in the ECM in a structure referred to as
pericellular matrix or glycocalyx (122). HA conformational changes by TSG-6 through
heavy chain transfer from inter-α-inhibitor, as well as binding to versican and aggrecan
may modify this structure (123). This higher order structure also plays a role in
development and in cancer cell survival (124, 125). One of the most described HA
receptors is CD44. This receptor also binds other ECM components such as collagen
and fibronectin but has HA dependent activity that results in cell motility and
inflammation changes as well as HA clearance (126). Another important receptor of HA
is Receptor for HA-Mediated Motility (RHAMM) which has been linked to proliferative
responses and motility in smooth muscle cells as well as participating in acute lung
injury (127, 128). Additionally Hyaluronic Acid Receptor for Endocytosis (HARE) and
Layilin act as HA receptors in certain cell types where they are associated with
endocytosis activation and epithelial barrier function respectively (129-131). HA plays a
role in many biological functions by interacting with special domains in cell surface
receptors and other ECM components. These functions include cell fate and organ
development, injury response, cell migration including cancer progression, as well as
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playing an important role in maintaining a well hydrated matrix (120). However,
depending on the context HA seems to have contradicting effects. One of these
contradicting effects in the seeming opposing forces of high molecular weight(HMW)
HA in an anti-inflammatory activity and low molecular weight(LMW) HA in a proinflammatory activity (132). While it is suggested that receptor interaction changes due
to molecular weight could play a role here, it is also indicated that inter-α-inhibitor
modification of HMW HA is reversible while LMW modification is not reversible (133).
This is important because inter-α-inhibitor modification greatly increases inflammatory
cell recruitment by HA (134). Early studies on the effect of HA on proliferation showed
a marked decrease in cellular proliferation when treated with HA (135). As studies began
to look at more cell types and cells in different conditions it was found that HA can
robustly increase proliferations in other circumstances (136, 137). While it has been
shown that this is at least partially due to differences in molecular weight, it is also
linked to differences in receptor recognition and downstream signaling (136).
Additionally, LMW HA is strongly linked to angiogenesis through the ephrin receptor
A2 (138). Refer to (Figure 3) for an illustration of the HA pathway.
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Figure 3 Hyaluronan Enzymes and Interactions
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Hyaluronan and Disease
Altered Hyaluronan production and degradation have been associated with
various diseases. Extensive research has shown that HA and HA related enzymes play
important roles in cancer, especially in cell survival, proliferation, and metastasis (120).
Colon and breast cancer lines express high levels of Hyal1 and Hyal2 as well as CD44
and depletion of HAS2 resulted in reduced cancer phenotypes (139-141). HA levels in the
serum of diabetic patients are raised and adipose CD44 signaling has also been
associated with this disease (142, 143). HA overexpression in mouse models of
atherosclerosis leads to increased plaque formation, potentially through CD44 signaling
in macrophages and smooth muscle cells (144, 145).
HA has been found to play an important role in multiple lung diseases. As HA
regulates inflammation, it is not surprising that HAS2 mutations have been found to
be associated with asthma (146). Additionally, HA is elevated in asthma patients and
increased HA is related to worsened symptoms (147). Cells isolated from patients have
elevated HAS2 levels and produce lower molecular weight HA than cells from healthy
patients (148). HA level changes are associated with COPD, where augmented levels of
HA and HAS2 expression has been reported (149). Some groups looking at specific
subsets of COPD patients or looking specifically at airway smooth muscle cells have
reported reduced levels of HA, HAS1 and HAS2 (150, 151). Increased HA deposition is
also associated with IPF. Patients with IPF have increased HA in the bronchoalveolar
lavage fluid compared to healthy individuals (152). Additionally, fibroblast cultured
from these patients show increased HA deposition with increased HAS2 expression
(153). The bleomycin mouse model also shows increase HA deposition while HAS2
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knockout mice show improvements in fibrosis (153). Exogenous hyaluronidase
treatment in this model has been shown to attenuate fibrosis (154). Of note, increased
HA levels have been observed in patients with Group 1 PH, associated with increased
HAS1 and HYAL1 expression (155). Excessive HA has also been observed in the plasma
of patients with PH associated with congestive heart failure and COPD (156). This
association has also been observed in the rat monocrotaline model as well as the
adenosine deaminase (ADA) deficient mouse model of lung injury (157, 158). This
evidence along with the role of HA in eliciting cellular response similar to those seen
in PASMCs in PH indicates that the role of HA in PH should be further investigated.
This thesis will untangle some of this pathway in PH.

26

Dissertation Overview
PH is a chronic lung disorder with increasing prevalence which has a great
impact on the quality of life and mortality of hundreds of thousands each year (1, 5). PH
patients typically have 5 year survival rates below 70% and PH is a common and
significant comorbidity with other chronic lung disease, serving as one of the most
significant indicators of poor prognosis (3). One of the patient groups greatly affected
by PH is those that also present with chronic lung diseases such as IPF or COPD (1).
Within this cohort of patients with chronic lung diseases, patients presenting with a
rare presentation of combined pulmonary fibrosis and emphysema (CPFE) have a
higher prevalence of PH (19). Up to 90% of CPFE patients develop PH and this diagnosis
reduces the survival rate from 55% for 5-year to 1-year survival rates of only 60% (159).
Understanding the molecular and cellular mechanism that give rise to these diseases is
important as few therapies exist and no curative treatments are available outside of lung
transplantation (7). This thesis explores two such mechanisms; NUDT21 induced APA
and increased HA deposition.
Previous studies have indicated that APA is an important regulatory mechanism
during the transcription of mRNAs (105). APA events induced by reduced level of
NUDT21 have been implicated in cancers and IPF (113-115). In some diseases NUDT21
depletion correlated with increased proliferation and changes in cell migration similar
to those seen in the PASMCs during PH progression (113). The role of NUDT21 in
controlling the phenotype of PASMCs has not been described and no link to PH has yet
been proven.
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HA is a glycosaminoglycan that makes up a large portion of the lung ECM. This
molecule is an important structural component linking many proteins together and
often controlling cell adhesion, while also being an important signaling molecule
binding several receptors including CD44 and RHAMM in vascular smooth muscle (127,
160). In disease states such as IPF, HA synthesis and degradation are dysregulated and
increased levels of HA have been measured in patients and animal models of PH and
secondary to fibrosis and other lung injuries (153). A complete understanding of the role
of HA and the many enzymes involved in its production, degradation, and signaling in
PH has not been gained. This project hypothesizes that NUDT21 depletion and
aberrant HA accumulation are important drivers of PH through changes in
PASMC phenotype

Specific Aim 1: Determine the role of NUDT21 depletion and subsequent APA in
the development of PH.
Patient samples and healthy controls were measured for NUDT21 and other
CFIm complex member levels by immunohistochemistry staining and western blotting
showing decreased levels. Using the hypoxia-sugen mouse model and the NUDT21F/Tagln-CreKI mouse line it was shown that depletion of NUDT21 contributes to
worsened PH symptoms. In cell culture of healthy and PH PASMCs it was shown that
low NUDT21 levels are associated with increased proliferation and reduced migration
in a Boyden chamber assay. The results of this aim are presented in Chapter 3.
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Specific Aim 2: Determine the role of hyaluronan in the development of
pulmonary hypertension.
I show that 4-Methylumbelliferone (4MU), a drug that inhibits HA production,
is sufficient to reduce PH symptoms in the hypoxia-sugen model of PH and bleomycin
model of lung fibrosis and PH. It was also shown that deletion of HAS2 from the
PASMCs of mice in the hypoxia-sugen model reduces PH. HA, HAS1 and HAS2 levels
were seen to be associated with PH by western blot and RT-PCR. These results were
recapitulated in the bleomycin model of lung fibrosis and PH. PASMCs treated with
small fragments of HA present with increase proliferation, migration and stiffness, all
hallmarks associated with PH. These results are presented in Chapter 4.

Specific Aim 3: Determine the role of HA in PH associated with CPFE.
CPFE is complicated disease in which PH plays an important and deadly role.
Patient samples of this disease show an increase in HAS3 expression and HA
accumulation. A novel model of CPFE, adenosine deaminase (ADA-/-) deficient mice,
confirmed these findings. Here I show that 4-MU reduced HA levels in the ADA-/- mouse
model of PH. These findings were associated with a reduction in fibrotic deposition and
PH, though no changes in airspace enlargement were seen. As the ADA-/- model
recapitulates adenosine accumulation and signaling seen in CPFE patients, I showed
that HAS2 and HAS3 are upregulated in an adenosine A2B receptor dependent manner
in vitro. The results of this aim are presented in Chapter 5.
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Identifying novel mechanisms that contribute to the development and
progression of PH will lead to increased understanding of the pathogenesis of disease
and eventually newly targeted therapies for the treatment of PH. The pathways
described here are exciting new mechanisms that control the phenotype of PASMC and
may be directly responsible for a portion of the vascular remodeling seen in PH as well
as one of the first mechanisms described for the progression of CPFE.
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Chapter 3: Loss of NUDT21 links APA with PH

Introduction
The vascular changes associated with PH include aberrant proliferation, cell
growth and abnormal vasoconstriction and the development of complex vascular
lesions (161). These changes in cell phenotype happen in several cell types but here I will
focus on PASMCs as they form the large medial section of pulmonary arteries and can
provide multiple mechanisms of vascular changes (162). Understanding the molecular
pathways that lead to changes in PASMC phenotype is important in understanding the
initiation and development of this disease. As APA has been recently described as a
driver of multiple disease states, most provocatively in cancer and IPF, I hypothesize
that NUDT21 loss and resulting APA may contribute the the development if PH by
altering the PASMC phenotype (114, 163).
The addition of poly(A) tails is a key process in the maturation of mRNA. An
mRNA containing multiple polyadenylation sites in the 3’UTR may undergo a process
known as 3’ UTR APA, in which the non-canonical polyadenylation site is used, leading
to an alternate transcript (164). As these alternate polyadenylation sites often occur
early in the 3’UTR a hallmark of this APA is 3’UTR shortening that leads to loss of
binding sites for regulatory elements such as miRs allowing transcripts to escape mRNA
regulation resulting in heightened levels of affected transcripts as well as allowing for
changes is translation efficiency(112). Depletion of NUDT21, a RNA binding protein in
the CFIm complex, is an important driver of 3’UTR APA (113, 165). This type of APA has
been found to drive cell proliferation and invasion in cancer (113). While NUDT21
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depletion can cause a few examples of other types of APA introduced in Chapter 2, this
research will focus on 3’UTR APA (112). As many of the hallmarks of cancer, including;
sustained proliferation, resistance to cell death, angiogenesis, and invasion, are
recapitulated in the cells of patients with PH, especially PAH, I focused on the role of
NUDT21 driven APA to control the phenotype of PASMCs and contribute to PH (166).
My results reveal that NUDT21 is depleted in isolated PASMCs of patients with
PH, both Group 1 and IPF + PH. This depletion was also recapitulated in a model of
Group 1 PH, the hypoxia-sugen mouse. Additionally, mice with heterozygous removal
of NUDT21 in PASMCs had increased PH symptoms over control mice. I also report a
phenotypic change in human PASMCS with depletion of NUDT21 associated with an
induction of proliferation and reduced migratory capacity. I also report several
pathways which are enriched in APA events after NUDT21 depletion, including a
shortening of the HAS2 gene and concomitant increases in HAS2 mRNA levels. These
results show evidence for a novel role for NUDT21 regulated APA to control cell
phenotype and contribute to disease progression in PH.

Results
NUDT21 is depleted in patients with Group 1 or Group 3 PH
I first stained lung sections from healthy donors and patients diagnosed with
PAH or IPF + PH for αSMA and NUDT21 expression. Serial sections were stained for
NUDT21 and αSMA or DAPI and αSMA. I then quantified the cells that were αSMA
positive with either NUDT21 staining or DAPI positive nuclei. This showed that patients
with PAH or IPF + PH have reduced nuclear NUDT21 in remodeled vessels compared to
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healthy vessels (Figure 4A-B). I then used flash frozen tissue samples to measure levels
of CFIm complex members in the pulmonary artery of patients with PAH compared to
control by western blot. Here I see a depletion in the level of NUDT21, CFIm59, and
CFIm68 (Figure 4C-D). CPSF73 is an important part of the cleavage and polyadenylation
machinery but is not a part of the CFIm complex and also does not change in level in
PAH samples (Figure 4C-D). Subsequently, I performed a western blot on samples from
healthy pulmonary arteries, arteries from lungs with IPF and arteries from lungs with
IPF + PH. Interestingly here, I only saw a change in NUDT21 in the IPF and IPF + PH
with no further depletion between IPF and IPF + PH. Meanwhile, CFIm59, CFIm68, and
CPSF73 have no significant change (Figure 4E-F). Taken together this suggests that
NUDT21 depletion is associated with PH.
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Figure 4 NUDT21 depletion in PH.
Sequential lung sections double stained for α-smooth muscle actin (α-SMA; red signals)
and NUDT21 (brown signals) from normal lungs (left) or patients with PAH (middle) or
IPF + PH (right) (A). Quantification of NUDT21 positive nuclei in α-SMA positive cells
and sequentially stained DAPI (ratio NUDT21 positive nuclei to DAPI) (B).
Immunoblots for NUDT21, CFIm59, CFIm68, CPSF73 and GAPDH from Normal and
PAH pulmonary arteries (C). Densitometries from C normalized to GAPDH(D).
Immunoblots for NUDT21, CFIm59, CFIm68, CPSF73 and GAPDH in Normal and IPF
and IPF + PH pulmonary arteries (E). Densitometries from E normalized to GAPDH(F).
The N used for panel B 13 (Normal); 12 (PAH); 10 (IPF+PH). Data are shown as mean ±
SD.* P ≤ 0.05
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Figure 5 Hypoxia-sugen model of PH shows reduced pulmonary artery NUDT21.
Right Ventricle Systolic Pressure (RVSP) (A); Left Ventricle Systolic Pressure (LVSP)(B);
Fulton index determined from measuring dry weights of RV and LV + septum (C).
Immunoblot for NUDT21, CFIm68 and βactin (D). Densitometries of D normalized to
βactin (E).

The N number used for these studies are 6 (Normoxia); 8 (HX-SU).

Significance level * P ≤ 0.05
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NUDT21 in the hypoxia-sugen model of PH
I next wanted to verify that the depletion of NUDT21 seen in patient samples is
recapitulated in a model of PH. In this experiment I used the hypoxia-sugen mouse
model. Here mice of ~8 weeks are exposed to hypoxic condition of 10% O2 for 28 days.
To further the model and prevent vascularization the mice are also treated weekly with
20mg/kg of Sugen 5416, IP a vascular endothelial growth factor receptor antagonist. At
day 28 hemodynamics of the mice are measured and the mice are sacrifice to obtain
samples. These mice have a significant rise in Right Ventricle Systolic Pressure (RVSP),
a measure similar to mPAP of patients (Figure 5A). The Left Ventricle Systolic Pressure
(LVSP) is not elevated in this model indicating no change in systemic blood pressure.
These mice also have significant Right Ventricle Hypertrophy (RVH) (Figure 5C). My
study showed that NUDT21 is depleted in the isolated pulmonary artery of these mice
(Figure 5D-E). I also see depletion of CFIm complex member CFIm68 (Figure 5D-E).
This indicates that this model is relevant for studying NUDT21 induced APA and PH.

NUDT21 deficient mice are more susceptible to PH
The Cre-Lox system is a very powerful tool for the genetic manipulation of mice.
I acquired the NUDT21-Flox mouse line and crossed it with the Tagln-CreKI mouse line
(114, 167). The Tagln-CreKI expresses cre recombinase from a knock in transgene at the
transgelin gene locus. This allows for recombination of loxp sites that were introduced
surrounding several exons of the NUDT21 gene in the NUDT21-Flox line. This allows for
the specific deletion of NUDT21 from vascular smooth muscle cells. Unfortunately, the
homozygous NUDT21-Flox Tagln-CreKI animals are embryonic lethal so I continued
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with only a heterozygous knock out. In addition, there are no available mice with
inducible expression of Cre in vascular smooth muscle cells. I then exposed these
animals to the hypoxia-sugen model and measured hemodynamics and NUDT21
expression. I show that even in normoxic conditions NUDT21 heterozygous KO is
sufficient to increase the RVSP significantly, but when exposed to hypoxia-sugen these
mice develop an augmented increase in RVSP (Figure 6A). Hypoxia in control mice was
able to reduce NUDT21 levels by nearly half, a similar level to the heterozygous KO mice
in normoxic conditions (Figure 6C-D). This data suggests that NUDT21 is a causative
agent in PH and that understanding the mechanism is important for understanding this
disease.
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Figure 6 PASMC KO of NUDT21 worsens pulmonary hypertension.
TaglnCre Normoxia, Nudt21f/+ TaglnCre Normoxia, TaglnCre Hypoxia-sugen, Nudt21f/+
TaglnCre Hypoxia-sugen. RVSP (A); LVSP(B); Immunoblot for NUDT21 and
GAPDH(C). Densitometries of C normalized to GAPDH (D). The N used for these
studies are 5 (TaglnCre Normoxia); 10 (Nudt21f/+ TaglnCre Normoxia); 10 (TaglnCre
Hypoxia-sugen); 9 (Nudt21f/+ TaglnCre Hypoxia-sugen) for panel A and 5 (TaglnCre
Normoxia); 5 (Nudt21f/+ TaglnCre Normoxia); 7 (TaglnCre Hypoxia-sugen); 8 (Nudt21f/+
TaglnCre Hypoxia-sugen) for B. Variations in N are due to violation of a predetermined
criteria: heart rate below 250 BPM at the time of LVSP.
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NUDT21 controls the phenotype of PASMCs
To determine the role that NUDT21 played in controlling PASMC phenotype, I
harvested and cultured these cells from healthy donors and lungs from patients with
PAH. I first measured the proliferative capacity of the healthy PASMCs by starving them
for 72 hours followed by treatment with control or NUDT21 siRNA. I then stimulated
the cells with vehicle or 25µM PDGF for 48 hours and then measured proliferation using
the WST1 assay. This demonstrated that depletion of NUDT21 increased PASMC
proliferation after 25µM PDGF (Figure7A). I then measured the proliferative phenotype
of cells isolated from PAH patients. These results demonstrate that PASMC derived
from patients with Group 1 PH present with an enhanced proliferative response to
PDGF. Interestingly, overexpressing of NUDT21 from the pcDNA3.1 plasmid attenuated
the enhanced proliferative phenotype of PAH-derived PASMC (Figure 7A). I used these
same groups to examine migratory ability. Here I used Boyden chambers with 8µm
pores (168). These allow cells to pass through but do provide a resistance. Then I
implement either a control or serum gradient to induce migration. In this experiment I
see reduced migration in the healthy cells when NUDT21 is reduced by siRNA (Figure
7B). Overexpression of NUDT21 in PH PASMCs showed no change in migration due to
sample variability.
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Figure 7 Changes in NUDT21 level induces phenotype changes in PASMCs

PASMCs isolated from healthy donors with control siRNA or NUDT21 siRNA are
stimulated with 25mM PDGF, PASMCs isolated from PAH patients with Empty Vector
(EV) or NUDT21 over expression vector (OE) are stimulated with 25mM PDGF, WST-1
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proliferation assay relative to unstimulated (A). PASMCs isolated from healthy donors
with control siRNA or NUDT21 siRNA in a Boyden chamber assay 1% is no serum
gradient, 10% is serum gradient (B). PASMCs isolated from PH patients with Empty
Vector (EV) or NUDT21 over expression vector (OE) in a Boyden chamber assay 1% is
no serum gradient, 10% is serum gradient (C). Data are shown as mean ± SD.* P ≤ 0.05
# P≤ 0.05
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Pathways controlled by NUDT21 mediated APA in PASMCs
After showing the phenotypic alterations caused by NUDT21 loss I sought to
understand the pathways that could be driving this change. To do this I utilized human
PASMCs (Lonza CC-2581) in culture. I used a siRNA to deplete NUDT21 in these cells
and harvested RNA. This RNA was then put through a library preparation procedure for
Illumina MiSeq. The sequencing was then performed and the bioinformatics technique
dynamic analysis of alternative polyadenylation (DaPars) was used to analyze the data
(169). This algorithm identified 664 shortened transcripts and 350 lengthened
transcripts (Figure 8A). My next step was to identify the functional pathways that are
enriched in the shortened data set. To do this I utilized the ConsensusPathDB that not
only defines pathways by gene product activity but also by protein-protein interactions
and regulatory interactions (170). In doing this the pathways with the most hits were
metabolism related genes, extracellular matrix, and cell proliferation (Figure 8B). To
visualize the changes discovered by the DaPars algorithm the RNA-seq traces for VMA21
are shown here (Figure 8C). VMA21 is very consistent in its shortening during reduced
levels of NUDT21 making it an excellent control for NUDT21 mediated 3’UTR APA.
Finally, I show the confirmation of NUDT21 depletion by siRNA as well as showing that
this change is sufficient to induce the expression of Col1 and Fn in cell culture (Figure
8D).
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Figure 8 RNA-seq exposes global APA changes in PASMCs after NUDT21
depletion
Plot of Percent Distal Usage Indexs(PDUI) of control vs change in PDUI in NUDT21
siRNA

treated

cells,

shortened

transcripts

blue

lengthened

orange(A).

ConsensusPathDB pathways enriched in shortened transcripts (B). Example trace or
shortened trace, VMA21 (C). Immunoblot of NUDT21, Col1, Fn, and GAPDH from si-con
and si-NUDT21 treated cells (D).
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Confirmation of NUDT21 mediated APA by RT-PCR
I then wanted to confirm the shortening events seen in the RNA-seq data. The
best way to confirm this is by RT-PCR to determine distal polyadenylation site usage.
To do this two RT-PCR primer sets are designed, one primer set in the coding sequence
which will measure both a short and long transcript, and one primer set distal of the
first major poly(A) site which will only measure the distal transcript. The log2 of the
difference of the Ct value of these primers gives the fold change in dPAS usage. Here I
verify VMA21 dPAS usage as well as one of the identified shortening targets within the
ECM pathway from the ConsensusPathDB, HAS2 (Figure 9A). This negative dPAS usage
indicates a shift from distal to proximal poly(A) usage and shortening of the mRNA
transcripts. VMA21 showed very robust shortening, as expected, while HAS2 presented
with a more moderate but nearly a 50% change in dPAS usage. I then measured total
transcript levels of these genes and demonstrated that both VMA21 and HAS2 are
significantly increased (Figure 9B). Next, I purified RNA from the isolated pulmonary
artery of healthy donors and patients with PAH to measure APA. I show that there is a
trend towards shortening in these samples in both VMA21 and HAS2 (Figure 9C). This
shortening is also accompanied by increases in total transcripts though VMA21 change
is non-significant (Figure 9D). These data confirm that NUDT21 depletion leads to
shortening in select transcripts in PASMCs in culture. While these shortening events
are not seen in these human samples due to biological variation, transcript levels are
significantly increased.
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Figure 9 RT-PCR verification of shortening in PASMCs

DPAS usage in VMA21 and HAS2 transcripts after NUDT21 siRNA treatment normalized
to control siRNA treatment (A). Expression levels of VMA21 and HAS2 using 18S rRNA
as a control (B). dPAS Usage of VMA21 and HAS2 from PAH pulmonary arteries
normalized to healthy pulmonary arteries(C). Expression levels of VMA21 and HAS2
normalized to 18S (D).
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Discussion
A major finding of my research is that NUDT21 levels are reduced in PH patients
and that depletion of NUDT21 drives the development of PH experimentally. This
reduction is consistent with the hypothesis that NUDT21 depletion leads to 3’UTR APA
and changes in mRNA transcripts that lead to PH. In fact, my finding that heterozygous
deletion of one copy of NUDT21 in mice PASMCs increases the PH that these mice
acquire in the hypoxia-sugen model is a strong indicator that this mechanism plays an
important role in the worsening of this disorder. This adds PH to the list of diseases that
have recently been shown to be partially or whole driven by APA, including several in
which NUDT21 level are key (112, 114). The results are highly important as they give a
new target for research and drug development in a disease that is not well controlled
with current therapies and lacks a curative treatment without transplantation.
NUDT21 is depleted in glioblastoma tumors and reduced levels of NUDT21 have
been reported in fibroblast from patients with IPF (163). In these fibroblast, NUDT21
reduction leads to increased TGFβ and Wnt signaling by altering gene expression
through APA. These changes result in a more fibrotic phenotype with the increases of
collagen and fibronectin expression. IPF fibroblast in culture also showed this synthetic
phenotype but resembled healthier fibroblast with the addition of exogenous NUDT21
(114). This change in phenotype encouraged me to explore the changes in cell phenotype
seen in PH and investigate the role of NUDT21 induced APA. My findings indicate that
healthy PASMCs, with reduced levels of NUDT21 by siRNA have an increased
proliferative potential when induced by PDGF. This high level of proliferative potential
matches that seen in PASMCs from patients with PH. This finding is consistent with the
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proliferative phenotype of patient cells seen in other studies (171). Alternately, migratory
capacity appears to be reduced with reduced level of NUDT21 in a Boyden chamber
assay with and without serum gradient. This is an unexpected result as I hypothesized
that increased migration would occur to accompany increased proliferation as was seen
in glioblastoma cell lines and is often seen in PASMCs exposed to hypoxia (113, 172). It
may be though that proliferation increased to such a speed that migration was inhibited
by the necessity of continued growth. An alternative explanation is that NUDT21
depletion leads to increased ECM deposition, precluding cell migration. Evidence for
this is present from PASMCs where increased Fn and Col1a1 expression was observed
following NUDT21 KD. This would indicate a potential intermediate phenotype with
increased proliferation and synthesis but reduced migration. These results show that
NUDT21 depletion regulates the phenotype of PASMC inducing changes similar to
PASMCs isolated from patients with PH. This is consistent with previous findings of
increased proliferation in PASMCs in PH (173).
In PASMC derived from patients with PH, rescuing expression of NUDT21
reversed their hyper-proliferative phenotype. This indicates that NUDT21 is a highly
promising target for pharmacological inhibition of PH. One of the challenges of
targeting NUDT21 is that it is a core member of the cleavage and polyadenylation
machinery and that activity of this complex is necessary for proper cellular survival. To
circumvent this problem I have two options, target specifically the pulmonary artery
cells or look to the interactions within the CFIm complex.
Increasing expression of NUDT21 in the PASMC would be an excellent
therapeutic target if it can be done very selectively and subtly. Recent advances in
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nanoparticle deliver could allow for treatment of PASMCs with a small oligonucleotide
(174). This was successfully used to target miR-145, which is associated with PAH, in the
hypoxia-sugen mouse rat model (175). Targeting a miRNA which regulates NUDT21 or
depletion of an upstream effector with RNAi through this delivery mechanism is a
potential therapeutic approach for PH.
An interesting finding was that in PAH all three CFIm complex members are
downregulated in in the pulmonary artery. Conversely, I see no such change in CFIm59
or CFIm68 in IPF or IPF + PH samples. This difference could point to a key separator in
the development of PAH when compared to Group 3 PH. If this is the case it is important
to further investigate these findings to understand potential interventions.
Additionally, understanding the role of each CFIm member allows me to target
interactions within the complex to make more subtle changes to the APA landscape.
While the exact role of CFIm59 and CFIm68 are unknown, some hypothesize that they
convey specificity in RNA binding to the complex during the formation of a tetramer
(176). If this is true, drug screens for NUDT21 mediated APA will likely target the protein
interactions that bind this complex.
NUDT21 regulated APA is a broad mechanism that changes the transcriptional
landscape in a cell. These changes can cause shortening in many genes as seen in HeLa
cells and caused shortening in over 600 genes in the samples (113). This large number of
genes that are regulated can make uncovering the smoking gun for changes seen due to
this APA difficult, thus I first looked at the pathways that were enriched in those genes
that were shortened by NUDT21 depletion. In my RNA-seq dataset I saw modulation of
several pathways that are linked to the phenotypic changes in PASMCs I observed in
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patient samples. These include pathways involved in proliferation and migration and
ECM. In fact, I showed that NUDT21 depletion in PASMCs in cell culture was sufficient
to cause an increase in Col1A and Fn depositions. This suggests that NUDT21 reduction
also induces a synthetic phenotype in these cells. As studying each APA event
discovered to describe the change it induces in PASMC is not feasible I selected a gene
which as described in the next chapter, is an important driver in PH; this gene is HAS2.
RNA-seq data can have many factors that cause anomalies in the data including
hard to sequence regions with repetitive sequences or other sequence features. This
makes it important to verify this data with other techniques. Here I verified the data
with additional RT-PCR experiments. This also allowed me to measure gene level
changes as a result of shortening. This was very exciting, as it revealed that NUDT21
depletion leads to shortening of the HAS2 mRNA in cell culture as well as patient tissue.
This change appears to lead to increased transcript level of HAS2. The following
chapters will discuss the consequences of increased HAS2 in PASMC of patients with
PH.
The results shown here indicate that NUDT21 levels are reduced in patient
samples of PH. This reduction is also recapitulated in the hypoxia-sugen mouse model.
When mice in this model have additionally reduced levels of NUDT21 the PH symptoms
are severely worsened, pointing to a role of NUDT21 in the progression of this disease.
To determine the mechanism that leads to this worsened PH, I described the
phenotypic changes seen in PASMCs with depleted NUDT21. These phenotypic changes
resemble differences seen between healthy and PASMC isolated from PH patients. I
then determined that NUDT21 reduction leads to widespread APA events in PASMCs
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and that the shortening events are enriched for pathways such as metabolism,
proliferation and ECM. I verified the shortening and increased expression of one target,
HAS2 by RT-PCR. Together these results describe an important role for NUDT21
mediated APA in the development and progression of PH. Understanding the role other
CFIm members play in these cells as well as more completely describing the APA
landscape changes seen in patients with PH will allow for targeted research and therapy
discovery in this newly discovered mechanism of PH development.
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Chapter 4: Uncovering the role of Hyaluronan in the pathogenesis of PH

This chapter is based upon research originally published in the British Journal of
Pharmacology. Collum SD, Chen NY, Hernandez AM, Hanmandlu A, Sweeney H,
Mertens TCJ, Weng T, Luo F, Molina JG, Davies J, Horan IP, Morrell NW, AmioneGuerra J, Al-Jabbari O, Youker K, Sun W, Rajadas J, Bollyky PL, Akkanti BH, Jyothula S,
Sinha N, Guha A, Karmouty-Quintana H. Inhibition of hyaluronan synthesis attenuates
pulmonary hypertension associated with lung fibrosis. Br J Pharmacol +Q,`.

Introduction
As discussed previously, the ECM is an integral compartment of all tissues and
plays a large role in the development of a healthy lung as well as the progression of
chronic lung diseases (177, 178). To understand the progression of diseases such as PH,
I must identify the important components of this matrix and dissect the influence these
molecules

have

on

the

cells

involved

in

disease

progression

(65).

The

glycosaminoglycan, HA, is a key structural component of the lung surrounding large
vessels and airways but where this molecule plays its most crucial role is signaling
through multiple pathways to induce cellular changes (160).
Increased levels of hyaluronan have been observed in patients with IPF and PAH
(150, 155, 179, 180). Furthermore, overexpression of hyaluronan synthase 2 (HAS2), an
enzyme responsible for the synthesis of hyaluronan, has been implicated in fibrosis
(153). Taken together, these observations suggest a role for hyaluronan in the
pathophysiology of PAH as well as IPF + PH. However, hyaluronan-mediated vascular
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remodeling and the mechanisms promoting increased hyaluronan synthesis in Group 1
and Group 3 PH is not fully understood. These observations prompted me to evaluate
the role of HA in the vasculature in Group 1 PH. I was also prompted to evaluate the
presence of elevated hyaluronan in patients with IPF and IPF + PH and to assess the
therapeutic potential of a hyaluronan synthase inhibitor in a murine model of Group 1
PH as well as PH associated with lung fibrosis.
4-Methylumbelliferone (4MU), also known as hymecromone, is a FDA approved
drug for bile therapy and it is also able to inhibit hyaluronan synthesis by depleting the
cell of uridine diphosphate-glucuronic acid, an essential substrate for all HAS isoforms
and by down-regulation of HAS2 and 3 mRNA expression (181-183). Increased levels of
HA have been measured in PAH both in the plasma of patients as well as in cultured
PASMCs from these patients (180). Additionally, the monocrotaline rat model shows
increased HAS2 expression as well as increased HA deposition and aberrant degradation
of HA (157).
My results show that therapy with 4MU and conditional genetic deletion of
smooth muscle HAS2 prevent the development of hallmarks of PH induced by chronic
exposure to hypoxia and sugen. I also have found that increased hyaluronan was
associated with remodeled vessels and correlated with increased disease severity in PH
associated with IPF, as defined by elevated mPAP values. In addition, I report
improvements in PH but not fibrosis following therapy with 4MU in the bleomycin
mouse model, which models PH associated with lung fibrosis (184). These observations
provide evidence for an independent hyaluronan-mediated mechanism in the
pathogenesis of PH associated with IPF. Furthermore, my results reveal that hyaluronan
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leads to increased proliferation and stiffness of PASMCs and also affects the ability of
these cells to migrate in a RhoA-dependent manner. Taken together, these results show
evidence of a unique mechanism contributing to PH.

Results
4-Methylumbelliferone (4MU) prevents pulmonary hypertension in the hypoxia-sugen
model
To investigate PH without lung parenchyma damage such as seen in Group 1 PH,
the hypoxia-sugen mouse model has been used (155, 185). This model recapitulates
many of the symptoms of this disease including vascular remodeling more resembling
the pathology seen in PAH patients with heavily exacerbated increases in pulmonary
blood pressure and eventual loss of cardiac output (55, 185). This model involves
subjecting the mice to 10% O2 for 28 days with four injections of SU5416 a vascular
endothelial growth factor receptor (VEGFR) inhibitor. These mice were treated with
4MU starting at day 14 and measurements and tissues were collected on day 33. In this
model, I see deposition of HA around the pulmonary vasculature that is reduced by
4MU treatment (Figure 10A). There is an increase in RVSP at day 28 in hypoxia-sugen
groups vs controls, this increase was removed by 4MU treatment (Figure 10B). LVSP
remained unchanged indicating no change to systemic pressures, while a hypoxia-sugen
induced right ventricle hypertrophy as measured by Fulton index was reduced by 4MU
treatment (Figure 10C –D).
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PASMC deletion of HAS2 prevent PH in the hypoxia-sugen model
As stated earlier the HA producing enzyme HAS2 is upregulated in the
monocrotaline rat model of PH (157). To further dissect the role of HAS2, which has
been associated with multiple disease states (153, 186), in these experiments I also
utilized the Has2f/f-TaglnCre mouse line. This line is a knockout of the expression of
HAS2 in vascular smooth muscle cells with no phenotype in nomoxic mice. At day 28 I
see that RVSP which is increased in control HAS2f/f hypoxia-sugen mice was reduce
towards normal with LVSP showing no changes (Figure 11A-B). Interestingly there is no
effect of HAS2 KO on RVH (Figure 11C).
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Figure 10 4MU prevents pulmonary hypertension in the hypoxia-sugen model.
IF-stained lung sections (A) for αSMA (green) and HA (red) from mice treated with
Normoxia + vehicle, Hypoxia-sugen + vehicle, or Hypoxia-sugen + 4MU. RVSP (B);
LVSP(C); Fulton index determined from measuring dry weights of RV and LV +
septum (D). Data are shown as scatter plot showing the mean ± SD. **** P ≤ 0.05,
significant difference between PBS + vehicle and bleomycin (BLM) + vehicle
treatment; ANOVA. # P < 0.05, significant difference between BLM + vehicle and BLM
+ 4MU treatment; ANOVA. The N used for these studies are 10 (Normoxia + vehicle);
4 (Normoxia + 4MU); 10 (Hx Su + Vehicle); 5 (Hx Su + 4MU) for panel B. Variations
in N are due to violation of a predetermined criteria: heart rate below 250 BPM at the
time of LVSP. The scale bar represents 50 μm.
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Figure 11 PASMC KO of HAS2 prevents pulmonary hypertension.
HAS2f/f Normoxia, HAS2f/f hypoxia-sugen, HAS2f/fTaglnCre . RVSP (A); LVSP(B); Fulton
index determined from measuring dry weights of RV and LV + septum (C). Data are
shown as scatter plot showing the mean ± SD. * P ≤ 0.05, significant difference
between HAS2f/f + Normoxia and HAS2f/f + Hx Su; ANOVA. # P < 0.05, significant
difference between HAS2f/f + Hu Su and HAS2f/f – TaglnCre + Hu Su; ANOVA. The scale
bar represents 50 μm. The N used for A is 3 (HAS2f/f + Normoxia); 4 (HAS2f/f + Hx Su);
5 (HAS2f/f – TaglnCre + Hu Su). Variations in N are due to violation of a predetermined
criteria: heart rate below 250 BPM at the time of RVSP or LVSP.
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Hyaluronan is elevated in patients with Group 3 pulmonary hypertension
HA deposition is increased in IPF and HA levels are associated with PH
secondary to COPD (153, 158). No study has shown a link between HA and IPF + PH. I
stained lung sections from patients diagnosed with IPF and those with IPF + PH. I found
increased hyaluronan levels, observed histologically, in IPF patients compared to
controls. This increase appeared to be enhanced further in patients with IPF + PH in
areas adjacent to the smooth muscle but not in the endothelial layer (Figure 12A).
Interestingly, increased hyaluronan deposition was observed in areas rich in vascular
remodeling (Figure 12A). Transcript levels of HAS1, HAS2 and HAS3 (Figure 12B–D) from
isolated lung sections revealed a significant correlation between elevated HAS2 and
HAS3 expression but not HAS1 expression levels and increased mPAP values for patients
with IPF (Figure 12B–D). Similarly, immunofluorescence for HAS2 and HAS3 revealed
increased signals for HAS2 and HAS3 in remodeled vessels of patients with IPF + PH
but not in IPF or normal (Figure 13A). Immunoblots for HAS1, HAS2 and HAS3 revealed
increased expression of HAS1 and HAS2 in IPF + PH samples compared with normal
and in IPF + PH compared with IPF groups (Figure 13B). Taken together these results
suggest that hyaluronan accumulation is present in fibrotic lung diseases and is
increased in patients with an additional diagnosis of PH.
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Figure 12 Increased hyaluronan levels and degradation in Group III PH.
Lung sections double stained for α-smooth muscle actin (α-SMA; red signals) and
hyaluronan (blue signals) from representative normal lungs (top panel) or patients with
IPF (middle panel) or IPF + PH (bottom panel) (A). Linear regression and Spearman
correlation analysis for mRNA levels for HAS1 (B; r = 0.1375, P>0.05), HAS2 (C; r = 0.6110,
P<0.05), HAS3 (D; r = 0.5144, P<0.05), HYAL1 (E; r = 0.2394, P>0.05), HYAL2 (F; r =
0.5932, P<0.05) and HYAL3 (G; r = 0.3560, P>0.05) ratio to geometric mean of control
genes HPRT1 and SDHA against mPAP from patients with IPF. The scale bar represents
100 μm. n = 6 (Control); 10 (IPF); 9 (IPF + PH). PH is defined as mPAP ≥25 mmHg.
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Figure 13 HAS2, HAS3, NRF2 and CD44 levels in human samples.
Immunofluorescence (IF) for HAS2 (red signals), or HAS3 (green signals) and αSMA
(white signals) for normal IPF and IPF + PH vessels (A); scale bar represents 50 μm. (B)
Immunoblots for HAS1–3, HYAL1–3, CD44 and βactin from 3 normal, 3 IPF and 3 IPF +
PH lung tissue samples. Linear regression and Spearman correlation between NRF2
expression levels and mPAP values for patients with IPF with or without a diagnosis of
PH (C). Linear regression and Spearman correlation with CD44 expression levels (D).
Expression levels for HAS1–3 and HYAL1–3 showing direct comparisons between IPF
and IPF + PH samples (E). Significance levels * P ≤ 0.05 refers to comparisons between
IPF and IPF + PH values.
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Increased hyaluronan degradation in Group 3 pulmonary hypertension
Hyaluronan can be degraded into low molecular weight fragments by
hyaluronidases and increased ROS (187, 188). Interestingly I report a significant
correlation between enhanced expression of hyaluronidase 2 (HYAL2) and mPAP
(Figure 12F) and elevated HYAL2 signals by immunoblots between IPF and normal but
not between IPF and IPF + PH. I also show increased protein levels for HYAL3 between
IPF and normal lung but no increases between IPF + PH and IPF but similar results were
not seen for HYAL1 or HYAL3. (Figure 12E–G) Immunoblots for HYALs revealed an
overall increase in IPF compared with normal groups and a further increase in IPF + PH
groups compared with IPF (Figure 13B). Finally, I report a significant correlation
between increased expression of Nrf2, a marker of increased oxidative stress, and
elevated mPAP (Figure 13C). Small MW hyaluronan fragments have been reported to
interact with CD44 to mediate pathogenic effects and I therefore measured CD44 levels
(177, 189). However, my data appears to show a reduction in CD44 protein levels despite
a correlation between increased CD44 and mPAP levels (Figure 13D, E). Expression
levels of all HAS and HYALs (IPF vs. IPF + PH) are shown in Figure 13. Taken together,
these observations show increased hyaluronan deposition in IPF and IPF + PH and
suggest that degradation of hyaluronan to smaller MW fragments is mediated by
enhanced expression of HYALs and the presence of ROS.
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4-Methylumbelliferone (4MU) reduces hyaluronan levels in a model of lung fibrosis and
PH
In this experiment, I treated mice exposed to bleomycin or vehicle, with 4MU
starting on day 15, consistent with previous studies from the lab where changes in the
lung parenchyma are apparent at this time point (190). On day 33, physiological
readouts and tissues were collected (Figure 14A). This is the intraperitoneal bleomycin
model that creates a more chronic fibrosis compared to the more commonly utilized
intratracheal bleomycin model. This model produces fibrosis progression from the
distal portion of the lung more in line with that seen in patients. Eight twice weekly
injections are performed and then the model progresses until day 33. BLM induces lung
fibrosis due to the relative lack of bleomycin hydrolase in the lung (191).
Hyaluronan levels observed by immunohistochemistry (IHC) show increased
hyaluronan deposition in bleomycin-exposed mice that were treated with 4MU therapy
(Figure 14B). In line with this, bronchoalveolar lavage fluid (BALF) revealed a significant
elevation of HA in bleomycin-exposed mice that was attenuated by 4MU treatment
(Figure 14C). These observations were consistent with increased levels of Has1, Has2 and
Has3 expression in bleomycin-exposed mice (Figure 14D-F) 4MU attenuated Has2 and
Has3 but not Has1 expression (Figure 14D–F). Analysis of hyaluronidases demonstrated
increased protein levels of Hyal1 and Hyal2 in bleomycin and bleomycin + 4MU
treatment groups compared to PBS consistent with increased Hyal2 but not Hyal1 or
Hyal3 mRNA expression levels (Figure 15B–D). Transcript levels for Nrf2 were elevated
in bleomycin, compared to PBS, groups (Figure 15E). These observations echo my
studies with human lung, showing evidence for increased hyaluronan fragment
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degradation in experimental lung fibrosis. Here I also measured CD44 levels and I report
increased both protein and mRNA levels in bleomycin-exposed mice (Figure 15A, F).
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Figure 14 Reduction of hyaluronan levels with 4MU in lung fibrosis and PH.
Experimental mice are treated biweekly for 4 weeks with bleomycin (BLM; 0.035 U/g,
i.p.) or PBS; 20 mg/kg/day 4MU or normal chow was administered beginning on day 15
until the end of the experiment (A). IHC (B) for hyaluronan from PBS + vehicle, PBS +
4MU, BLM + vehicle and BLM + 4MU treatment groups. Hyaluronan levels determined
from BALF (C); mRNA levels from lung lysates for Has1 (D); Has2 (E) and Has3 (F) using
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TATA-box binding protein (TBP). Data are shown as scatter plots showing the mean ±
SD. * P ≤ 0.05, significant difference between PBS + vehicle and BLM + vehicle
treatment; ANOVA. # P < 0.05, significant difference between BLM + vehicle and BLM
+ 4MU treatment; ANOVA. The scale bar represents 50 μm. The N used for these studies
are 5 (PBS + vehicle); 6 (PBS + 4MU); 8 (BLM + vehicle); 7 (BLM + 4MU) for panel C and
5 (PBS + vehicle); 6 (PBS + 4MU); 8 (BLM + vehicle); 5 (BLM + 4MU) for panels D–F.
Variations in N are due to violation of a predetermined criteria: presence of blood in
BALF (C) or repeatedly poor RNA quality and loss of sample (D–F).
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Figure 15 Hyaluronidases in mouse samples.
Immunoblots of 2 PBS [+vehicle], 3 BLM [+vehicle] and 3 BLM + 4MU for Hyal1, Hyal2,
Hyal3, Cd44 and βactin (A). Transcript levels for Hyal1 (B), Hyal2 (C), Hyal3 (D), Cd44
(E) and Nrf2 (F). The N number used for these studies are 5 (PBS + Vehicle); 6
(PBS + 4MU); 8 (BLM + Vehicle); and 5 (BLM + 4MU). Significance level * P ≤ 0.05 refers
to ANOVA comparisons between PBS + Vehicle and BLM + Vehicle treatment groups.
Variations in the N number are due to violation of a predetermined criteria: repeatedly
poor RNA quality and loss of sample (B-D).
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4-Methylumbelliferone (4MU) prevents vascular remodeling and PH
Using a mouse model of lung fibrosis and PH, I show increased vascular αsmooth muscle actin (αSMA) deposition in addition to Has1, Has2 or Has3 expression
consistent with vascular remodeling in bleomycin-exposed mice compared to controls
(Figure 16A) (190). Treatment with 4MU in bleomycin-exposed mice led to a reduction
in αSMA deposition and Has1, Has2 or Has3 expression levels observed by
immunofluorescence (Figure 16A) and assessed morphometrically (Figure 16B). These
changes are in-line with physiological readouts of pulmonary hypertension such as
RVSP where I report increased pressures in bleomycin-exposed mice that were
significantly attenuated in the bleomycin + 4MU group (Figure 16C). Similarly, the
Fulton index, a measure of RVH revealed increased values in bleomycin-exposed mice
that were significantly inhibited in 4MU-treated bleomycin-exposed mice (Figure 16D).
I also report a significant improvement in arterial oxygenation (SpO2) in bleomycin+
4MU treated mice compared with bleomycin-exposed mice where reduced oxygenation
is apparent compared to controls (Figure 16E). No changes in LVSP or heart rate were
observed between treatment groups (Figure 17A, B). Taken together my data show that
4MU can prevent vascular remodeling and the subsequent development of PH in the
model. In addition, I performed bioanalysis by LC–MS/MS to determine the levels of
4MU and its metabolite 4-methylumbelliferyl-β-D-glucuronide (4MUG) from plasma
samples. Interestingly I report increased levels of 4MU in bleomycin-exposed 4MUtreated mice compared with PBS-exposed 4MU groups (Figure 17C). 4MUG levels were
elevated in both bleomycin and PBS exposed mice that received 4MU in the diet (Figure
17D).
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Figure 16 4MU prevents vascular remodeling and pulmonary hypertension.
IF-stained lung sections (A) for αSMA (white or red signals) and Has1 (violet/purple
signals); Has2 (green signals); or Has3 (green signals) from mice treated with PBS +
vehicle, bleomycin (BLM) + vehicle, or BLM + 4MU. Vascular remodeling determined
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morphometrically (B); RVSP (C); Fulton index determined from measuring dry weights
of RV and LV + septum (D); arterial oxygen (SPO2) determined by pulse oximetry (E)
from PBS + vehicle, PBS + 4MU, BLM + vehicle and BLM + 4MU treatment groups. Data
are shown as scatter plot showing the mean ± SD. * P ≤ 0.05, significant difference
between PBS + vehicle and BLM + vehicle treatment; ANOVA. # P < 0.05, significant
difference between BLM + vehicle and BLM + 4MU treatment; ANOVA. The scale bar
represents 50 μm. The N used for these studies are 6 (PBS + vehicle); 6 (PBS + 4MU); 7
(BLM + vehicle); 5 (BLM + 4MU) for panel B; and 10 (PBS + vehicle) for panel B and 10
(PBS + 4MU); 10 (BLM + vehicle); and 8 (BLM + 4MU) for panels C, D and E. Variations
in the N are due to violation of a predetermined criteria: inadequate inflation of the
lung (C) or heart rate below 250 BPM at the time of RVSP or inability to perform pulse
oximetry determination (C–E).
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Figure 17 Additional hemodynamic data and 4MU / 4MUG levels in plasma.
Left ventricle systolic pressure (LVSP) (A) and heart rate (B) from PBS (PBS) + vehicle,
PBS + 4MU, bleomycin (BLM) + vehicle, and BLM + 4MU treatment groups. Data is
shown as a scatter plot showing the mean ± SD. The N number used for these studies
are 8 (PBS + Vehicle); 7 (PBS + 4MU); 7 (BLM + Vehicle); and 6 (BLM + 4MU) for panel
A and 10 (PBS + Vehicle); 10 (PBS + 4MU); 10 (BLM + Vehicle); and 8 (BLM + 4MU) for
panel B. Plasma levels for 4-methylumbelliferone (4MU) and its metabolite: 4methylumbelliferyl-β-D-glucuronide (4MUG) from PBS + Vehicle; PBS + 4MU;
BLM + Vehicle; and BLM + 4MU treatment groups. n = 5 for all groups. Significance
level * P ≤ 0.05 refers to ANOVA comparisons between PBS + Vehicle and BLM + Vehicle
treatment groups. # P ≤ 0.05 refers to ANOVA comparisons between PBS + 4MU and
BLM + 4MU treatment groups. Variations in the N number are due a violation of a
predetermined criteria: heart rates below 250 BPM at the time LVSP determination (A)
or below 250 BPM at the time of RVSP determination (B).
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Fibrotic deposition is not altered in 4MU-treated mice
Numerous studies have shown a role for hyaluronan in the pathophysiology of
lung fibrosis (152, 153, 180). Based on these observations, I anticipated that 4MU
treatment would diminish the extent of fibrotic deposition in bleomycin-exposed mice.
Interestingly, I report that treatment with 4MU did not reduce the extent of fibrotic
scarring in the lungs as shown histologically (Figure 18A) or following Ashcroft score
grading (Figure 18B). These observations are consistent with Col1a1 and Fn1 transcript
levels showing elevated expression in bleomycin-exposed mice that were not inhibited
in bleomycin + 4MU mice (Figure 18C, D). Consistent with these observations, an
immunoblot for fibronectin (FN) shows increased FN signals in bleomycin-exposed
mice compared with controls, that were not altered in bleomycin + 4MU mice (Figure
18E) and staining for SMA shows no difference in myofibroblast deposition between
bleomycin-exposed mice following vehicle or 4MU treatment (Figure 18F). Collectively,
these results suggest that 4MU, although able to inhibit vascular remodeling, may not
influence fibrotic deposition at the dose and regimen used in this study.
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Figure 18 Fibrotic deposition is maintained in 4MU-treated mice.
Masson's trichome (A); Ashcroft scores (B); transcript levels for Col1a1 (C) and Fn1 (D);
and immunoblots for FN and β-actin (E) from PBS + vehicle, PBS + 4MU, bleomycin
(BLM) + vehicle and BLM + 4MU treatment groups. Lung sections IF stained for αSMA
(green signals) and counterstained with DAPI (blue signals) (F) from BLM + vehicle or
BLM + 4MU treatment groups. Data are shown as scatter plot showing the mean ± SD.
* P ≤ 0.05, significant difference between PBS + vehicle and BLM + vehicle treatment;
ANOVA. The scale bar represents 50 μm. The N used for these studies are 5
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(PBS + vehicle); 5 (PBS + 4MU); 5 (BLM + vehicle); and 5 (BLM + 4MU) for panel B and
5 (PBS + vehicle); 6 (PBS + 4MU); 8 (BLM + vehicle); and 5 (BLM + 4MU) for panels C
and D. Variations in the N are due to violation of a predetermined criteria: repeatedly
poor RNA quality and loss of sample (B–D).
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4MU treats established PH
I next examined the capability of 4MU to treat established PH. In this
experiment, mice received 4MU or vehicle (control chow) starting on day 33 (Figure
19A), a time point where PH is present in the model (Figure 19A), for 14 days. Consistent
with my previous experiment, 4MU resulted in reduced mRNA expression of Has1, Has2
and Has3 observed from flash-frozen lung samples and vascular protein levels shown by
immunofluorescence (IF) (Figure 19B–D). Remarkably, I report higher RVSP levels on
day 47 in mice treated with control chow compared with mice on day 33, that are
drastically attenuated following treatment with 4MU (Figure 19E). Interestingly, 4MU
did not appear to affect RVH when therapy started on day 33 (Figure 19F). No changes
in LVSP were observed in these mice (Figure 19G). Consistent with my previous results,
4MU did not affect fibrotic deposition as observed histologically and through Ashcroft
scores (Figure 6A, B). RT-PCR for Col1a1, Col1a2 and Col3a1 did not reveal differences
between bleomycin + 4MU and bleomycin + vehicle treatment groups (Figure 20C–E).
Interestingly, no significance differences between Hyal1, Hyal2, Hyal3 and CD44 at the
mRNA or protein level were detected between bleomycin + vehicle and bleomycin +
4MU groups (Figure 20F–I). However, reduced levels for RhoA guanine nucleotide
exchange factor 25 (GEFT), a signaling protein seen to act downstream of CD44 (192),
were found in bleomycin-exposed 4MU-treated mice compared to bleomycin-exposure
and vehicle treatment (Figure 20I). Determination of hyaluronan fragment size in
isolated lung tissue revealed increased LMW hyaluronan fragments in bleomycinexposed mice compared to controls; 4MU treatment reduced total hyaluronan fragment
size, particularly LMW-HA (Figure 20J). Taken together, these results highlight the
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properties of 4MU in reversing PH associated with lung fibrosis, despite not inhibiting
FN and Col1a1 levels. These results also show that 4MU does not appear to have an effect
on Hyal expression levels but that it may also alter GEFT levels that may be important
for PH.
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Figure 19 4MU attenuates established pulmonary hypertension.
Here mice are treated biweekly for 4 weeks i.p. with bleomycin (BLM; 0.035 U·g−1, i.p.)
or PBS; 20 mg·kg−1·day−1 4MU or normal chow was administered beginning on day 33;
once PH was established for 2 weeks, measurements were performed on day 47 (A).
mRNA expression levels and IF staining for Has1 (violet/purple signals) and αSMA
(white signals) (B); Has2 (red signals) and αSMA (white signals) (C) and Has3 (green
signals) and αSMA (white signals) (D) normalized to β-actin (Actnb). RVSP (E), RVH
determined from measuring dry RV and LV + septum masses (F); and LVSP (G); BLM +
vehicle and BLM + 4MU treatment groups. Data are shown as scatter plot showing the
mean ± SD. * P ≤ 0.05, significant difference between BLM + vehicle and BLM + 4MU
treatment; unpaired Student's t-test. The N used for these studies are 5 (BLM + vehicle);
and 5 (BLM + 4MU).
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Figure 20 4MU does not affect fibrotic deposition in established PH.
Masson's trichrome-stained lung sections (A) and Ashcroft scores (B) from bleomycin
(BLM) or BLM + 4MU-treated mice. Expression levels of Col1a1 (C), Col1a2 (D), Col3a1
(E), Hyal1 (F), Hyal2 (G) and Hyal3 (H) normalized to β-actin (Actnb). immunoblots
(I) for Hyal1, Hyal2, Hyal3 Cd44, GEFT and β-actin for four representative mice from
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BLM + vehicle and BLM + 4MU treatment groups. Hyaluronan fragment size (J) from a
PBS (lane 1), BLM + 4MU (lane 2) or a BLM-exposed (lane 3) lung. The red rectangle
highlights an area with LMWHA fragments showing a greater density in lane 3. Data
are shown as scatter plot showing the mean ± SD (Panels B–H). The N used for these
studies are 5 (BLM + vehicle); and 5 (BLM + 4MU).
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Increased vascular hyaluronan-binding protein 2 (HABP2) is observed
Studies have shown that HABP2, an extracellular serine protease that binds
hyaluronan and has been implicated in mediating endothelial dysfunction (193).
Interestingly, in my study, I show increased levels of HABP2 in remodeled vessels from
mice exposed to bleomycin compared with controls, that are subsequently reduced in
bleomycin-exposed mice treated with 4MU (Figure 21). In line with these observations,
I report increased HABP2 in and adjacent to remodeled vessels in the lung from patients
with IPF + PH compared to IPF and normal lungs (Figure 22A). In support of these data,
an immunoblot for HABP2 revealed increased levels in IPF + PH patient samples
compared to IPF or normal lungs (Figure 22B, C). Studies have implicated increased
signaling of HABP2 and hyaluronan complexes through a RhoA mechanism (193). As
such, I examined whether increased signals for GEFT, a protein that interacts with Rho
GTPases and is involved in the activation of RhoA and subsequent contraction of
vascular smooth muscle (194). Indeed, I report increased GEFT in lung lysates from
patients with IPF + PH compared to normal or IPF alone (Figure 22D, E). Remarkably,
increased HABP2 was only observed in remodeled vessels and not in fibrotic lesions of
the lung as observed in mice lungs exposed to bleomycin and treated with vehicle or
4MU or in fibrotic lesions of patients with IPF + PH (Figure 23). These observations
suggest that the interaction between HABP2 and hyaluronan and subsequent RhoA
activation may be a unique mechanism contributing to PH associated with lung fibrosis.
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Figure 21 4MU reduces vascular HABP2 levels.
Lung sections triple immunofluroescently stained for αSMA (turquoise signals), HABP2
(yellow signals) and hyaluronan (violet/purple signals) and counterstained with DAPI
(white/grey signals) from PBS, bleomycin (BLM) or BLM + 4MU-exposed mice. The
scale bar represents 50 μm.
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Figure 22 Increased vascular HABP2 in patients with IPF and IPF + PH.
Lung sections from a pulmonary vessel showing triple immunofluroescent staining for
αSMA (turquoise signals), HABP2 (yellow signals) and HA (violet/purple signals) and
counterstained with DAPI (white/grey signals) (A); immunoblots for HABP2 and
GADPH (B); densitometry for HABP2 normalized to GADPH (C); immunoblots for
GEFT and β-actin (D); and densitometry for GEFT normalized to β-actin (E) from
normal lung tissue and from lung explants from patients with IPF and IPF + PH. The
scale bar represents 50 μm. * P ≤ 0.05, significant difference between normal and IPF +
PH values.
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Figure 23 HABP2 is not expressed in the lung parenchyma.
Lung sections triple immunofluroescently (IF) stained for αsmooth muscle actin (αSMA/ turquoise signals), HABP2 (yellow signals), and hyaluronan (HA; violet/purple
signals) and counterstained with DAPI (white/grey signals). No HABP2 signals are
observed in the lung parenchyma from patients with IPF.
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Hyaluronan fragments affect PASMC properties
Using human PASMC from normal areas of resected cancer tissue, I demonstrate
that MMW and LMW hyaluronan fragments lead to increased proliferation of PASMC
that is inhibited by fasudil, a Rho kinase inhibitor (Figure 24A); no significant
differences were seen in cytotoxicity between treatment groups (Figure 24B). I next
examined the capacity of these cells to migrate using a 3D cell culture protocol (195). In
these experiments, I report reduced cell migration in PASMC following treatment with
LMW-HA and ULMW-HA that was reversed following treatment with fasudil (Figure
24C). Surprisingly, atomic force microscopy (AFM) experiments revealed that MMW
and ULMW-HA fragments were both able to increase PASMC stiffness that was reversed
using fasudil (Figure 24E). AFM measurements were performed in the center of the cell
(Figure 24F). Taken together, these results demonstrate that hyaluronan fragments are
able to cause stiffening of PASMC and that LMW-HA induced increased proliferation
but reduced motility of these cells in a Rho-dependent manner that contribute to the
pathophysiology of PH associated with lung fibrosis.
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Figure 24 Hyaluronan affects PASMC properties.
Cellular proliferation (A) and cytotoxicity (B) from cells exposed to HMW, MMW, LMW
or ULMW hyaluronan treated with PBS or fasudil (100 μM). Migration assay for MMW,
LMW and ULMW (C).

Staining for Ki67, HABP2 and GEFT in cell culture after

treatment with ULMW HA and Fasudil (D). Atomic force microscopy experiments
showing increased cells stiffness using Young's modulus for PASMC treated with media
only, MMW or ULMW HA (E). Detail of the positioning of the AFM tip on the centre of
a PASMC (F). * P ≤ 0.05, significant difference between media and MWM + PBS, LMW
+ PBS or ULMW + PBS experimental, ANOVA. # P ≤ 0.05, significant difference between
PBS and fasudil treatment groups; unpaired Student's t-test.
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Discussion
A major finding of this study was that HAS2 expression is associated with
increased PH in patients with IPF. Additionally, we see increases in HAS3 and Hyal2
expression. Furthermore, these expression changes are associated with staining for HA
in patients with IPF, including those with secondary PH, near the pulmonary
vasculature. These findings are confirmed in the bleomycin model of lung fibrosis and
PH. Provocative results from this study demonstrate that treatment with 4MU, a
hyaluronan synthesis inhibitor that also targets HAS mRNA expression, prevented the
development of PH and treated established PH associated with lung fibrosis. My results
are remarkable as they show that 4MU is able to attenuate RVSP and vascular
remodeling, but it does not appear to affect fibrotic deposition in the lungs. In a second
model of PH, initial studies indicate 4MU also reduced RVSP and RVH while deletion
of the HAS2 gene from vascular smooth muscle cells was able to reduce RVSP without
changes to RVH. These results point at a unique mechanism for hyaluronan in the
pathogenesis of PH. Novel findings from my study demonstrate increased expression of
HABP2 and GEFT in remodeled vessels from patients with Group 3 PH and in
experimental models of PH and lung fibrosis. I also show that hyaluronan fragments
induce increased PASMC proliferation and stiffness of the cell and also affect cellular
migration in a RhoA-dependent fashion. Taken together, my results demonstrate that
elevated hyaluronan is modulating PH associated with lung fibrosis that can be treated
by inhibiting hyaluronan synthesis or RhoA activation. These results are significant
given the poor prognosis of patients with chronic lung diseases with an additional
diagnosis of PH, where no treatment options are available(196).
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Elevated hyaluronan has been reported in lung diseases including IPF and PH
and in PH associated with chronic obstructive pulmonary disease as well as PAH (153,
155, 158, 180, 189, 197). Consistent with these findings, I report increased hyaluronan
levels in IPF compared with normal lungs that are elevated further in patients with a
diagnosis of PH. Interestingly, my data show evidence for elevated HAS enzymes in
disease. These findings are significant as HAS2 has been shown to promote senescence
in fibroblasts in pulmonary fibrosis suggesting a similar pathogenic role for HAS2 in
PASMC (198). HMW hyaluronan fragments are typically associated with beneficial
properties with smaller fragments inducing pathogenic effects through its interaction
with cell membrane receptors such as CD44 (189, 199). Hyaluronidases and ROS have
been shown to degrade HMW hyaluronan to lower molecular weight fragments. In line
with this, I report increased levels of several hyaluronidases in IPF in addition to a
correlation between NRF2 transcripts and elevated mPAP levels in patients in IPF.
Taken together, these studies demonstrate that hyaluronan synthesis is up-regulated,
perhaps as a protective response, but that the higher levels of hyaluronidases and
oxidative stress lead to degradation of hyaluronan to pathogenic factors. Although the
mechanisms that lead to elevated expression of HAS and HYALs are not the focus of
this study, I anticipate that activation of the adenosine A2B receptor modulates this
process, consistent with the notion of elevated adenosinergic-hypoxic axis in PH
associated with IPF and the role of adenosine in modulating hyaluronan synthesis
associated with chronic obstructive pulmonary disease (158). It is well known that
higher molecular fragments of hyaluronan are beneficial (180). In addition, hyaluronan
has been shown to promote progenitor cell renewal and prevent severe fibrosis in mice
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(200). Therefore, an alternative approach to inhibiting hyaluronan synthases would be
to prevent the degradation of hyaluronan to the more pathogenic smaller fragments by
developing selective inhibitors of hyaluronidases. Interestingly, two patients from the
study cohort were treated with N-acetylcysteine, a compound known to inhibit
hyaluronidases (201). It is worth noting that these patients did not have a diagnosis of
PH and one had the lowest levels of mPAP in the cohort.
The mechanisms that lead to the development of PH associated with chronic
lung diseases are not fully understood (17, 202). Traditional views suggest that
eliminating the underlying chronic lung disease such as fibrosis will result in the
improvement of PH outcomes. Although studies have shown that inhibition of fibrotic
deposition or airspace enlargement in the lungs improves PH, the identification of a
unique mechanism leading to PH associated with lung fibrosis has been elusive (158,
190). Surprisingly, my results show that inhibiting hyaluronan synthesis by 4MU
prevents the development of PH and reduces established PH without affecting fibrotic
deposition in the lungs. An explanation for these results may reside in the fact that
although hyaluronan levels were reduced, the levels may still be high enough to
maintain fibroproliferative lesions. Alternatively, findings demonstrating a protective
role for hyaluronan in severe fibrosis could also help explain my findings (200).
These effects are consistent with reduced Has transcripts and vascular Has levels
seen by IF. Consistent with previous publications showing a beneficial effect for 4MU
my results demonstrate that 4MU treatment attenuated bleomycin-induced vascular
remodeling, elevated RVSP and RVH and led to an increased arterial oxygenation (203205). It is important to note that in experiments where 4MU was administered in
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established PH (on day 33 vs. 15), RVSP but not RVH was attenuated. In this model, I
believe that lung vascular remodeling precedes RVH; thus, I anticipate that in already
established PH, a longer treatment time may be necessary to have an effect on RVH.
Despite this, these results point at a potential use for 4MU in patients with IPF with the
aim of preventing the development of PH. Lowering elevated mPAP levels in patients
with Group 3 PH and preventing the development of PH in patients with IPF would be
a valuable clinical outcome, as PH in IPF is strongly associated with mortality (17).
However, it is important to note that despite these observations, there is still
controversy over whether treating PH in the setting of IPF improves survival, despite
early improvements in functional status and quality of life (206). However, in those
studies, the effects of a vasodilator were evaluated, and it remains possible that
therapies that are aimed to alter the process of vascular remodeling would have greater
beneficial effects (206). It is also important to mention that patients with IPF + PH who
have a lung transplant, have worse outcomes than those without PH, suggesting that
treating PH might lead to similar outcomes to those patients with IPF and no PH.
Moreover, reducing elevated mPAP levels in patients with chronic lung diseases and
out-of-proportion PH would enable these patients to become eligible for lung
transplantation, a procedure that is often unavailable for them. The doses of 4MU I have
used here, while lower than some studies, especially those that characterized the
pharmacokinetics of this drug, were able to produce a physiological response and
detectable levels in the plasma of the treated animals (207). This dose is similar to the
dose used in a human clinical study in motor disorders of the bile ducts (208). These
results may indicate that inhibition of HA production in the lung is possible with
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comparatively lower doses of 4MU, leading to the potential to use less drug and
consequently produce fewer side effects.
In my effort to identify how elevated hyaluronan may play a role in the
development of PH, I identified increased expression of HABP2 in remodeled vessels of
patients with Group 3 PH and in experimental models of PH and lung fibrosis.
Interestingly, increased HABP2 appeared to be localized in remodeled vessels and was
not observed in areas rich in fibroproliferative injury. Increased HABP2 has been shown
to down-regulate vascular integrity through a RhoA-dependent mechanism (193). In
line with this, I report increased expression of GEFT, an essential component of the
RhoA pathway activation that has been linked to hyperplasia of vascular smooth muscle
cells (209). In subsequent experiments, I demonstrated that LMW and ULMW
hyaluronan fragments induced increased proliferation of isolated human PASMC that
were inhibited by the RhoA inhibitor fasudil. These studies are consistent with the
capacity of hyaluronan to induce cellular proliferation and demonstrate a novel role for
fasudil in hyaluronan-induced PASMC proliferation (189, 197, 210). Furthermore, in
contrast to published experiments showing increased cellular migration by hyaluronan,
my studies show that cellular migration PASMC is drastically inhibited by LMW and
ULMW hyaluronan fragments in a RhoA-dependent manner (189, 197, 199). These
differences may derive from the fact that most cells where hyaluronan-induced cellular
migration has been reported are in cancer cells that are prone to migration. However,
my results showing reduced cellular migration are in line with increased PASMC
stiffness observed by AFM following exposure to hyaluronan (189, 197, 210). These
observations are consistent with increased vascular stiffness induced by hyaluronan
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accumulation in the aorta (177). Interestingly, in this study, increased proliferation of
vascular smooth muscle cells was also associated with increased hyaluronan
accumulation. This is consistent with experiments showing increased PASMC
proliferation when grown in substrates with similar stiffness as that seen in distal vessels
in PH (162). Taken together, my results show that increased HABP2 and GEFT are
present in remodeled vessels of patients with Group 3 PH. My data show evidence that
hyaluronan fragments are able to induce both cellular proliferation and increased
stiffness of PASMC while attenuating migration of these cells that contribute to the
development of PH. These findings would support the use of fasudil for the treatment
of Group 3 PH. Indeed, fasudil has been used in Group 1 PH where it has shown
promising results and is effective in models of lung fibrosis , although it’s potential as a
treatment for Group 3 PH has not yet been fully evaluated (179, 211, 212). Another
promising approach is the development of inhibitors of HABP2, a protein that is
strongly associated with the development of Group 3 PH and has recently been linked
with cancer (213).
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Chapter 5: Identifying the role of hyaluronan in Combined Pulmonary Fibrosis
and Emphysema

This chapter is based upon research originally published in Disease Models and
Mechanisms. Collum SD, Molina JG, Hanmandlu A, Bi W, Pedroza M, Mertens TCJ,
Wareing N, Wei W, Wilson C, Sun W, Rajadas J, Bollyky PL, Philip KM, Ren D,
Thandavarayan RA, Bruckner BA, Xia Y, Blackburn MR, Karmouty-Quintana H.
Adenosine and hyaluronan modulate lung fibrosis and pulmonary hypertension in
combined pulmonary fibrosis and emphysema (CPFE). Dis Model Mech 2019.

Introduction
In the previous chapter I have demonstrated the important role that HA plays in
the development of PH. I also indicate that though HA is associated with pulmonary
pressure increases, patients with IPF have increased HA over healthy individuals. This
is in line with previous studies indicating that HA signaling is important for invasive
fibroblast during the progression to severe lung fibrosis (153). In fact HA depositions
has long been a hallmark of lung fibrosis (214).
Continued research has shown that HA deposition and degradation play an
important role in COPD as well. Patients with severe COPD have increased levels of HA
and HYAL2 compared to control subjects (149). HA and HYAL activity have strong
correlations with survival time in patients with COPD (215). Additionally, a previous
publication from the Karmouty lab has shown increased levels of HA associated with
PH secondary to COPD in patient samples (158).
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However, whether abnormal HA synthesis and destruction are present in CPFE
is not known. CPFE is a complex disease where both fibrotic matrix deposition, similar
to IPF, is present and airspace enlargement, a hallmark of COPD, is also present in the
same lungs. Up to 90% of patients with CPFE also develop PH, a sever complication for
this disease. My results in the previous chapter, showing a mechanistic role of HA in
PH, and previous data showing strong correlation for HA with IPF and COPD indicate
that it may be a common mechanism that plays a role in CPFE. This motivated me to
investigate the role of HA in CPFE to investigate the shared role in fibrotic deposition
and emphysematic alveoli destruction.
Traditionally, COPD (specifically emphysema) and IPF are regarded as separate
disease entities. Nonetheless, hallmarks of both COPD and IPF were first described in
autopsies of lungs in 1974 (216); however, it was not until 2005 that this condition was
classified as a well-defined syndrome termed CPFE (217). Male smokers or ex-smokers
most often present with CPFE (217-219) and it has a dismal prognosis with only a 55%
survival rate at 5 years (217). CPFE is a distinct under-recognized syndrome where no
specific diagnostic guidelines are present, yet studies show that its presentation is much
more frequent than previously believed (159). An important and highly fatal comorbidity in CPFE is the development of PH (220). The prevalence of PH in CPFE ranges
between 47-90% and is much higher than in patients with IPF or emphysema alone (19,
26, 28, 159). Confirmation of PH by right-heart catheterization data plummets 1-year
survival rates to only 60% (26). Despite this dismal prognosis, no therapy options exist
for patients with CPFE outside of smoking cessation, oxygen therapy and lung
transplantation (27, 219). Specifically, for PH in CPFE, endothelin receptor antagonists,
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prostanoids and phosphodiesterase type 5 inhibitors have been used. However, these
agents are not recommended for PH in CPFE due to the vasodilation profile of these
agents resulting in ventilation/perfusion mismatch (28), highlighting the need to
develop novel treatment approaches for CPFE.
Although several gene mutations have been associated with CPFE, including
telomerase genes (hTERT or hTR), surfactant protein C (SFTPC) and ATP binding
cassette subfamily A member 3 (ABCA3), these have been performed in very small
familial cohorts (hTERT/hTR) or in case studies (SFTPC/ABCA3) (27). As such no single
gene defect is known be associated with CPFE and the mechanisms leading to the
development of CPFE remains vastly unknown (219). Despite this, studies in COPD and
IPF patients with PH have revealed increased activation of the adenosinergic axis and
enhanced levels of the glycosaminoglycan hyaluronan (158, 190, 221). In these studies,
increased activation of the adenosine A2B receptor (ADORA2B) was shown to enhance
expression of the hyaluronan synthases, contributing to the pathophysiology of chronic
lung disease (158, 190, 221, 222). Furthermore, several studies from our group, have
implicated macrophages in the pathophysiology of lung fibrosis and PH. In these
studies, deletion of myeloid ADORA2B was able to prevent BLM-induced PH and lung
fibrosis (222). Further studies from our group have also demonstrated an important link
between macrophage activation and ADORA2B expression promoting fibrotic lung
injury (223). These results point at macrophages as a potential mechanism promoting
lung fibrosis and PH, however whether they play a role in CPFE is not known.
Using a unique model of experimental lung injury that replicates features of
CPFE, namely airspace enlargement, PH and fibrotic deposition (158, 224), I investigated
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the capacity of a hyaluronan synthase inhibitor to attenuate features of chronic lung
injury and determined a link between hyaluronan expression and macrophages.

Results
Characterization of an experimental model of CPFE.
I used Ada-/- mice to model features of CPFE. Ada-/- mice received supplemental
PEG-ADA, allowing them to live normally, from birth up to week 24. Starting on week
24, PEG-ADA was gradually reduced over 9 weeks and starting on week 34 mice were
provided with control chow or medicated with 4MU for 4 weeks. The gradual reduction
of PEG-ADA results in accumulation of extracellular adenosine that is associated with
chronic injury (225).
A hallmark of CPFE is the presence of fibrotic deposition and airspace
enlargement. I determined the extent of fibrotic deposition first by staining lung
sections with Masson’s Trichrome and performing Ashcroft scores to determine the
extent of fibrosis. These experiments revealed a marked increase in fibrotic deposition
in Ada-/- mice compared to Ada+ mice that was significantly attenuated in Ada-deficient
mice treated with the hyaluronan inhibitor: 4-Methylumbelliferone (4MU) (Figure 25
A, B). These histological changes were consistent with expression levels of fibronectin
that were elevated in Ada-/- mice compared to Ada-competent mice. Therapy with 4MU
reduced Fn expression levels in Ada-/- mice (Figure 25 C). I next examined the extent of
airspace enlargement, a key feature of CPFE, in the mouse model using black and white
images of the lung parenchyma. Ada-/- mice presented with evidence of airspace
enlargement as observed histologically and by mean chord length measurements
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determined morphometrically in comparison to Ada+ mice (Figure 25 D, E). Treatment
with 4MU did not alter the emphysematous development in Ada-deficient mice (Figure
25 D, E), despite improved arterial oxygenation (SpO2) compared to Ada-/- mice exposed
to control chow (Figure 25F). The development of PH is a serious and common
complication of CPFE (26). A feature of PH associated with chronic lung disease is
vascular remodeling and hyaluronan deposition (158, 190, 226). In order to assess the
extent of vascular remodeling, I performed dual-IHC for SMA and hyaluronan. These
experiments revealed extensive muscularization of arterioles in Ada-/- compared to Ada+
mice that was significantly attenuated in 4MU-treated Ada-/- mice (Figure 25G).
Widespread hyaluronan deposition was observed surrounding remodeled vessels in
Ada-/- mice whereas no hyaluronan was present in parenchymal vessels of Adacompetent animals; 4MU treatment drastically reduced the levels of peri-vascular
hyaluronan in mice lacking ADA (Figure 25G). These observations were backed by
morphometric evaluation of vascular wall remodeling and hyaluronan levels in BALF
(Figure 25 H, I). These analyses demonstrated increased SMA signals in the remodeled
vessels of Ada-/- mice compared to Ada+ mice that were attenuated in Ada-/- mice
exposed to 4MU (Figure 25 H). BALF hyaluronan levels revealed patently increased
hyaluronan levels in Ada-/- compared to control mice that were markedly reduced in
Ada-/- + 4MU exposed mice (Figure 25 I). Taken together, my results show that my model
of Ada-/- mice presents with cardinal features of CPFE: fibrotic deposition, airspace
enlargement and vascular remodeling, a key component of PH. Furthermore, I
demonstrate that treatment of these mice with 4MU is able to attenuate both the
fibrotic deposition and vascular remodeling in Ada-/- mice.
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Figure 25 Features of chronic lung injury in Ada-/- mice and the effect of (4methylumbelliferone [4-MU]) or control chow.
(A) Representative Masson’s Trichome images showing fibrotic deposition in the in
Ada-/- mice (middle panel) compared to Ada+ mice (upper panel). The effect of 4-MU in
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Ada-/- mice is shown in the bottom panel. Aschroft scores from Masson’s Trichome
images (B) and mRNA expression levels of Fibronectin (FN, C) from Ada+(white bars),
Ada-/- (grey bars) and Ada-/- + 4MU treated mice (black bars). (D) Black and white
images of the lung parenchyma from Ada+ mice (upper panel), Ada-/- (middle panel) and
Ada-/- + 4MU treated mice (lower panel). Mean chord length determined histologically
(E) and arterial oxygen saturation (F) from Ada+ (white bars), Ada-/- (grey bars) and Ada/-

+ 4MU treated mice (black bars). (G) Representative dual-immunohistochemistry

staining for alpha smooth muscle actin (SMA, blue signals) and hyaluronan (magenta
signals) showcasing arterioles from Ada+ (upper panel) Ada-/- (middle panel) and Ada/-

+ 4MU (lower panel). Morphometric evaluation of SMA deposition from 5 to 7 vessels

for each mouse (H) and broncho-alveolar lavage fluid (BALF) levels of hylauronan (I)
from Ada+ (white bars), Ada-/- (grey bars) and Ada-/- +4MU treated mice (black bars).
For panels B, C, E, F, H, I data is presented as mean + SEM. *P< 0.05 refers to
comparisons between Ada+ and Ada-/- treatment groups. #< 0.05 refers to comparisons
between Ada-/- and Ada-/- + 4MU treatment groups. Scale bars represent 200 µm

98

Vascular physiology, metabolism and hyaluronan levels in Ada-/- mice.
Although vascular remodeling is a key feature of PH, right-heart catheterization
and determination of RVSP in mice is necessary to adequately evaluate the extent of
PH. As such, RVSP measurements were determined in my experimental model. I report
increased RVSP in Ada-/- mice compared to Ada+ mice that were attenuated in Ada-/- +
4MU mice (Figure 26A). Consistent with the phenomenon of PH, no differences in LVSP
were observed between treatment groups (Figure 26B). The RVSP data was
accompanied by evidence of right ventricle hypertrophy (RVH) in Ada-/- mice compared
to Ada+ littermates that did not appear to be significantly attenuated following 4MU
therapy (Figure 26C). In order to probe the mechanisms associated with the
development of PH, I next evaluated the expression levels of the Adora2b and evidence
of metabolic alterations. Enhanced adenosinergic axis and metabolic alterations have
been reported in Group 3 PH (158, 190, 221, 222). These experiments revealed heightened
Adora2b expression in Ada-/- mice but no expression in Ada+ or Ada-/- + 4MU mice
(Figure 26D). Consistent with dysregulated metabolism, I report reduced levels of Pparg
and Sdha that were not rescued following 4MU therapy (Figure 26 E, F). I next evaluated
the expression levels of hyaluronan synthases, which are known to be up-regulated by
ADORA2b activation. These experiments revealed elevated expression of Has3 but not
Has1 or Has2 in Ada-/- mice compared to controls that was significantly reduced
following 4MU treatment in Ada-deficient mice (Figure 26 G-I). Dual IHC for
hyaluronan and αSMA revealed increased hyaluronan deposition in fibrotic areas in
Ada-/- mice that was significantly attenuated following 4MU therapy (Figure 26J). These
results demonstrate that Ada-/- mice present with physiological features of PH including
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elevated RVSP and RVH in addition with increased Adora2b and Has3 expression,
concomitant with elevated hyaluronic acid deposition observed histologically. 4MU
therapy was able to attenuate the increased RVSP and hyaluronic acid deposition
associated with reduced Adora2b and Has3 expression levels, but did not affect the
dysregulated metabolic profile or reverse RVH.
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Figure 26 Cardiovascular physiology, metabolic profile and hyaluronan
synthesis and deposition in Ada-/- .
Right ventricular systolic pressure (RVSP, A), left ventricular systolic pressure (LVSP, B)
and Fulton Index ratio (C) determined by the measure of right ventricle and left
ventricle with septum from Ada+ (white bars), Ada-/- (grey bars) and Ada-/- +4MU treated
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mice (black bars). Transcript expression levels from lung tissue for Adora2b (D), Pparg
(E), Sdha (F), Has1 (G), Has 2 (H), Has 3 (I) by RT-PCR from Ada+ (white bars), Ada-/(grey bars) and Ada-/- +4MU treated mice (black bars). (J) Representative dualimmunohistochemistry staining in fibrotic areas of Ada-/- or Ada-/- + 4MU treatment
groups for alpha smooth muscle actin (SMA, blue signals) and hyaluronan (magenta
signals). Scale bars represent 200 µm. For panels A-I data is presented as mean + SEM.
*P< 0.05 refers to comparisons between Ada+ and Ada-/- treatment groups. #< 0.05 refers
to comparisons between Ada-/- and Ada-/- + 4-MU treatment groups. The N used for
these studies are 8 (Ada+); 13 (Ada-/-); 5 (Ada-/- +4MU). Variations in N are due to
violation of a predetermined criteria: heart rate below 250 BPM at the time of RVSP or
LVSP.
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Macrophages in Ada-/- mice.
An interesting feature of the Ada-/- mice was the presence of F4/80 positive cells
in the lung (Figure 27A), while treatment with 4MU resulted in an attenuation of F4/80+
cells in Ada-/- mice (Figure 27A, B). I next evaluated whether these cells were positive for
HAS3. Indeed, double-IHC for HAS3 and F4/80 revealed signals for HAS3 and F4/80 in
Ada-/- mice that appeared reduced following treatment with 4MU (Figure 27 C, D).
Interestingly, increased HAS3 signals were observed in vascular and epithelial cells.
Further IHC demonstrated that these HAS3-positive cells also expressed hyaluronan
and were observed close to vessels in Ada-/- mice (Figure 28 A). Treatment with 4MU
resulted in an attenuation of HAS3/hyaluronan positive cells and a marked reduction of
hyaluronan (Figure 28 A, B). These HAS3+ cells were also observed in areas rich in
myofibroblasts (observed using αSMA IF) that were reduced following 4MU treatment
(Figure 28 C, D). Our group has previously demonstrated that activation of hypoxic
adenosinergic axis in macrophages is important for the development of lung fibrosis
(222, 223). In these studies, reduced hyaluronan deposition was observed in mice
lacking Adora2b in myeloid cells (222). Thus, using MH-S cells, a murine macrophage
cell line, I next examined whether increased expression of the hyaluronan synthase
isozymes was Adora2b-dependent. These experiments revealed that Has2 and Has3, but
not Has1, was increased following treatment with the ADORA2b agonist Bay60-6583,
and that this response was inhibited by the presence of the ADORA2b antagonist GS6201 (Figure 29 A-C). This response was consistent with elevated BAY60-6583-induced
interleukin-6 that was inhibited by GS-6201 (Figure 29 D). IL-6 is a known pro-fibrotic
mediator downstream of macrophage ADORA2b stimulation (222, 223, 227). Taken
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together, these results point at an ADORA2b-mediated increase of HAS3-expressing
macrophages (F4/80 positive cells) that lead to increased hyaluronan deposition.
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Figure 27 Macrophages in Ada-/- mice.
(A) Immunohistochemistry for F4/80 (yellow signals) and nuclear DAPI stain showing
F4/80 positive cells in Ada+ (upper panel) Ada-/- (middle panel) and Ada-/- + 4MU (lower
panel). Scale bar represents 75 µm. (B) F4/80 positive cells from 10 micropictographs
from the lung parenchyma from Ada+ (white bars), Ada-/- (grey bars) and Ada-/- + 4MU
treated mice (black bars). *P< 0.05 refers to comparisons between Ada+ and Ada-/-
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treatment groups. #< 0.05 refers to comparisons between Ada-/- and Ada-/- + 4MU
treatment groups. (C) Dual immunohistochemistry for hyaluronan synthase 3 (Has3,
red/brown signals) and F4/80 (blue signals) in Ada+ (upper panel) Ada-/- (middle panel)
and Ada-/- + 4MU (lower panel). Scale bar represents 200 µm. (D) Double F4/80 and
HAS3 positive cells from 10 micropictographs from the lung parenchyma from Ada+
(white bars), Ada-/- (grey bars) and Ada-/- + 4MU treated mice (black bars). *P< 0.05
refers to comparisons between Ada+ and Ada-/- treatment groups. #< 0.05 refers to
comparisons between Ada-/- and Ada-/- + 4-MU treatment groups
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Figure 28 Macrophages in Ada-/- mice express HAS3.
(A) Dual immunohistochemistry for hyaluronan synthase 3 (Has3, magenta signals)
and hyaluronan (blue signals) in Ada-/- (upper panels) and Ada-/- + 4MU (lower panels).
Scale bar represents 100 µm. (B) Double HAS3 and hyaluronan positive cells from 10
micropictographs from the lung parenchyma from Ada-/- (grey bars) and Ada-/- + 4MU
treated mice (black bars). (C) Dual immunohistochemistry for hyaluronan synthase 3
(Has3, magenta signals) and alpha-smooth muscle actin (SMA green signals) in Ada-/(upper panels) and Ada-/- + 4MU (lower panels). Scale bar represents 75 µm. (D) Double
HAS3 and SMA positive cells from 10 micropictographs from the lung parenchyma from
Ada-/- (grey bars) and Ada-/- + 4MU treated mice (black bars). #< 0.05 refers to
comparisons between Ada-/- and Ada-/- + 4-MU treatment groups
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Figure 29 Response to macrophages to an ADORA2B agonist.
Experimental Design Mertens TCJ, Collum SD, Karmouty-Quintana H. Experiment
performed by and experimental data compliments of Mertens TCJ.

Transcript levels of (A)Has1, (B) Has2, (C) Has3, (D) IL6 of MH-S cells exposed to DMSO
(black bars); the Adora2b antagonist: GS-2601 (grey bars), the Adora2b agonist: BAY606583 (blue bars), or under the presence of both GS-2601 and BAY60-6583 (red bars). *P<
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0.05 refers to comparisons between DMSO and BAY60-6583 treatment groups. #< 0.05
refers to comparisons between BAY60-6583 and BAY60-6583 + GS-2601 treatment
groups.
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The adenosinergic response in CPFE.
Using explanted lung tissue derived from upper or lower lung lobes from CPFE
patients or from normal lungs that were discarded for transplantation, I evaluated
mediators involved in the generation and degradation of adenosine, in addition to
adenosine receptors. In CPFE, upper lobes often present with emphysema while fibrotic
deposition is more prevalent in lower lobes. Quantitative RT-PCR for the
ectonucleotidases CD39 and CD73 (Figure 30 A, B) demonstrated increased expression
of the rate limiting enzyme CD73 but not CD39 in lower lobes but not upper lobes of
CPFE compared to normal lung tissue (Figure 30 A, B). No differences were seen in ADA
expression levels from lung tissue derived from upper or lower lobes (Figure 30 C).
Equilibrative nucleoside transporters (ENT) also regulate extracellular adenosine levels
whereby reduced expression is associated with increased adenosine accumulation and
the development of lung injury (228).

However, I report no difference in ENT

expression in CPFE despite a downward trend for ENT-2 in lower lobes of CPFE lungs
(Figure 30D). Expression levels of adenosine receptors did not show significant
alterations in ADORA1 or ADORA2A between normal and CPFE lung tissue (Figure 30
E, F). However, increased expression levels of ADORA2B were detected in lower lobes
of CPFE compared to normal lungs but not in tissue derived from upper lobes (Figure
30 G). Similarly, to ADORA1 and ADORA2A, no significant differences in expression of
ADORA3 were observed between normal and CPFE-derived lung tissue (Figure 30 H).
Taken together, these results suggest that in CPFE, like in other chronic lung
diseases(225), increased adenosine synthesis is enhanced in concert with expression of
its low-affinity receptor, ADORA2B.
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Figure 30 The adenosinergic response in CPFE.
Lung transcript levels for (A) CD39, (B) CD73, (C) ADA, (D) ENT2, (E) ADORA1, (F)
ADORA2A, (G) ADORA2B, (H) ADORA3; from upper lobes from normal lungs (white
bars), upper lobes from CPFE lungs (light blue bars), lower lobes from normal lungs
(grey bars), and lower lobes from CPFE lungs (dark blue bars). *P< 0.05 refers to
comparisons between normal and CPFE groups within upper or lower lung lobes.
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The extra-cellular matrix in CPFE.
Next, I evaluated the protein levels of ADORA2B and HAS3 in CPFE. Protein
expression levels for ADORA2B revealed increased expression in lower lobes from CPFE
lung tissue vs normal controls, concomitant with increased signals for HAS3 (Figure 31
A-C). These observations were in-line with IHC for αSMA, revealing hyaluronan signals
in highly remodeled areas of lung characterized by dense myofibroblast presence and
prominent vascular remodeling in CPFE lungs compared to normal tissue (Figure 31 D).
Similarly, staining for HAS3 and CD68 (a human monocytic phagocyte marker) revealed
positive signals for CD68 and HAS3 in lower lobes of CPFE lungs (Figure 31 E, F). These
results did not show alterations in HAS1 or HAS2 between normal and CPFE lung tissue
derived from upper or lower lobes (Figure 32 A, B). Gene expression for fibrotic genes
revealed increased expression of FN1 in upper lobes of CPFE vs normal lungs but not in
lower lobes (Figure 32 C). Expression levels of COL1A1 revealed significantly increased
expression levels in lung tissue derived from lower lobes from CPFE vs normal lung
tissue (Figure 32 D). COL1A2 was significantly elevated in both upper and lower lobes
in CPFE vs normal lung tissue, whereas COL2A1 was elevated only in the lower lobes
from CPFE lungs (Figure 32 E, F). These collagens have previously been shown to
express in the lung and be associated with lung disease (73, 158, 229). Interestingly, these
results demonstrate that purinergic remodeling and increased ADORA2B levels in CPFE
are observed in the lower lobes were fibrotic deposition is most evident and in areas of
vascular remodeling, in line with the role of adenosine in promoting fibrotic deposition
and vascular remodeling in chronic lung injury (225).
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Figure 31 ADORA2B and HAS3 are elevated in CPFE.
Western blot for ADORA2B, HAS3 and GAPDH from upper and lower lobes from
normal or CPFE lungs (A). Densitometries for ADORA2B (B) and HAS3 (C) from upper
lobes from normal lungs (white bars), upper lobes from CPFE lungs (light blue bars),
lower lobes from normal lungs (grey bars), and lower lobes from CPFE lungs (dark blue
bars). (D) Dual immunohistochemistry for alpha smooth muscle actin (SMA, red/brown
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signals) and hyaluronan (blue signals) in normal (upper panels) or CPFE (lower panels)
lungs. The red V denotes vessels and the green asterisks point at myofibroblasts. (E)
Immunohistochemistry for CD68 (blue signals) and HAS3 (red signals) from lower lobes
from normal and CPFE lungs. Red arrows represent CD68 positive (HAS3 negative)
signals. Black arrows point at dual HAS3 and CD68 signals, scale bar represents 50 µm.
(F) Double HAS3 and CD68 positive cells from 10 micropictographs from the upper
lobes from normal lungs (white bars), upper lobes from CPFE lungs (light blue bars),
lower lobes from normal lungs (grey bars), and lower lobes from CPFE lungs (dark blue
bars). *P< 0.05 refers to comparisons between normal and CPFE groups within upper or
lower lung lobes.
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Figure 32 Extracellular matrix signals in CPFE.
Transcript levels for (A) HAS1, (B) HAS2, (C) FN1, (D) COL1A1, (E) COL1A2, (F) COL2A
from upper lobes from normal lungs (white bars), upper lobes from CPFE lungs (light
blue bars), lower lobes from normal lungs (grey bars), and lower lobes from CPFE lungs
(dark blue bars). *P< 0.05 refers to comparisons between normal and CPFE groups
within upper or lower lung lobes.
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Discussion
Despite reductions in mortality in cancer and cardiovascular disease, mortality
rates for chronic lung diseases including interstitial lung disease have remained
unaffected over the last decade(230). This is a direct result of disparate funding
allocated towards research in chronic lung disease that in no way reflects the heavy
societal burden of the disease (230). This translates to an overwhelming lack of effective
therapies for chronic lung diseases. CPFE represents a chronic lung disease syndrome
that has higher mortality and morbidity rates than diseases such as COPD or IPF. Like
other chronic lung diseases, limited therapeutic options exist outside lung
transplantation (27, 218, 219). Thus, there is a need to identify novel treatments that can
attenuate features of CPFE and improve the morbidity and mortality rates. In this study,
I have characterized an experimental model of CPFE using male 6-month-old Ada-/mice and demonstrated that they present with features of CPFE, namely fibrotic
deposition, airspace enlargement and PH. I have also generated preliminary results that
show that 4MU, also known as hymecromone, an FDA-approved drug, is capable of
attenuating fibrotic deposition and PH in a murine experimental model of chronic lung
injury that recapitulates features of CPFE. Furthermore, my studies utilizing lung
tissues derived from upper or lower lobes from explanted lungs from patients with CPFE
or from normal lungs that were discarded for transplantation, reveal an upregulated
adenosinergic response and evidence of increased hyaluronic acid deposition.
Evaluation of the potential mechanisms leading to increased hyaluronan in the
experimental model point at Adora2b-mediated Has3 expression in macrophages that
is supported by dual F4/80 and Has3 positive cells observed histologically.
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There is a lack of experimental models of lung disease that can accurately
recapitulate the pathophysiology of chronic lung diseases (231). This is particularly the
case for CPFE, where limited animal models that recapitulate its cardinal features
(fibrotic deposition, airspace enlargement and PH) have been described. Features of
CPFE have been modeled by treating mice with both the fibrotic agent bleomycin and
elastase to induce airspace enlargement (232, 233). Experiments have also been
performed treating cigarette-smoke exposed mice with the pro-fibrotic agents
bleomycin or herpesvirus leading to airspace enlargement and fibrotic matrix
deposition (234). Additionally, exposure to the halogen gas bromine (Br2) has also been
shown to induce combined airway fibrosis and emphysema (235). Although these
models are able to recapitulate features of CPFE, they rely on chemical-induced lung
injury, which does not accurately represent the etiology of CPFE (219). Furthermore,
these models have not characterized the presence of PH, an important feature of CPFE
(19, 26, 28, 159).
The Ada-/- mouse model of lung injury was first reported by Blackburn et al.(236,
237) and has demonstrated to recapitulate important features of chronic lung injury
such as fibrotic deposition, airspace enlargement and PH (158, 238, 239). In these studies
both male and female littermate Ada-/- and Ada+ mice were utilized and PEG-ADA
therapy was maintained typically up to post-natal day 21 whereupon it was
discontinued, leading to a rapid increase in extracellular adenosine levels resulting in
lung injury observed typically 15 to 20 days after cessation of PEG-ADA therapy (158,
238, 239). To adequately model CPFE, a disease that primarily affects males (217-219), I
utilized male 6-month old Ada-/- mice that were subjected to a progressive reduction in
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PEG-ADA therapy leading to a gradual increase in extracellular adenosine. Using this
approach, I aimed to mimic the repeated subclinical injury that is associated with
chronic lung diseases. Using this approach, mice presented with extensive remodeling
of the lung parenchyma including airspace enlargement, fibrotic deposition and
vascular remodeling and PH consistent with previous publications(158, 238, 239).
However, the extent of fibrotic injury and features of PH, such as RVSP, appeared
enhanced in the model of gradual reduction of PEG-ADA therapy using male mice.
An important therapeutic finding from my study was that 4MU was capable of
inhibiting PH in the Ada-/- mice, consistent with previous studies using bleomycinexposed mice that presented with fibrotic deposition and PH (226). However, contrary
to the study of Collum et al (226), this study demonstrates that 4MU is capable of
attenuating the fibrotic deposition in Ada-/- mice. This discrepancy could be explained
by the different treatment regimen of 4MU. In the present study, 4MU was
administered for 4 weeks whereas in the previous study it was only given for 2 weeks
(226). Thus the longer treatment regimen may explain the effect of 4MU at inhibiting
both PH and fibrotic deposition; this effect is supported by a greater reduction of
hyaluronan levels, observed by ELISA in BALF, in the present study using Ada-/- mice
compared to previous studies in the bleomycin model of lung fibrosis (226). These are
important pre-clinical results demonstrating that an FDA-approved drug has the
capacity of attenuating cardinal features of CPFE, a disease that currently lacks any
effective therapy outside lung transplantation (27, 219).
Consistent with previous publications from our group(158, 190), I demonstrate
that both elevated Adora2b expression and hyaluronan accumulation are present in the
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experimental model of lung injury. A novel finding of this study was that Has3, but not
Has1 or Has2 as in previously reported in models of lung injury (158, 190, 226), was the
main hyaluronan synthase that was upregulated in the experimental model. My results
are consistent with cigarette-exposed mice where increased lung hyaluronan and Has3
expression was observed (240). Interestingly, elevated Has3 signals were primarily
observed in macrophages in Ada-/- mice. In addition, increased Has3 expression in
macrophages was Adora2b-dependent, consistent with previous publications utilizing
mice lacking Adora2b-expression in the monocyte lineage (222) and from studies
demonstrating an Adora2b-dependent Has expression in pulmonary artery smooth
muscle cells (190, 226). Treatment with 4MU was able to attenuate Has3 expression
levels consistent with reduced hyaluronan accumulation and macrophages. These
results point at macrophages as an important contributor to the development of lung
fibrosis and PH, consistent with prior studies (222, 223, 241, 242) where alternativelyactivated macrophages were shown to promote the development of features of chronic
lung injury. It is important to mention that increased Has3 signals were also observed
in epithelial and vascular cells in Ada-/- mice that could also contribute to increased
hyaluronan accumulation. Increased vascular or peri-vascular expression of Has3 and
subsequent hyaluronan deposition could also contribute directly to vascular
remodeling and PH by promoting vascular stiffness and proliferation as demonstrated
previously by our group (226). Pulmonary artery smooth muscle cell expression of
hyaluronan synthases has been shown to be modulated by activation of Adora2b (55,
190). This is in line with studies showing Adora2b-mediated macrophage Has3
expression.
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A novel finding of this study was that Has3-expessing macrophages appeared to
contribute to chronic lung injury. This is significant, as typically Has3 is associated with
the generation of low-molecular-weight (LMW) hyaluronan fragments (243). These
LMW hyaluronan fragments are associated with pathogenic effects (189, 240).
Importantly, results from the experimental model were consistent with the presence of
HAS3-expressing CD68 cells in CPFE that was consistent with massive hyaluronan
deposition surrounding fibrotic areas and remodeled vessels from CPFE explanted
lungs. These results are highly significant since little is known regarding the pathogenic
mediators involved in the pathophysiology of CPFE.
It is important to mention that adenosine is a danger-associated molecular
pattern that is generated following cell injury and subsequent extracellular release of
ATP that is converted to adenosine by CD39 and CD73, with the latter being the ratelimiting enzyme (244). Adenosine can then activate any of its four receptors: ADORA1,
ADORA2A, ADORA2B and ADORA3 (245).

Adenosine is known to have many

protective effects acutely, however chronically elevated levels of adenosine and
subsequent activation of its low-affinity receptor, ADORA2B, has been extensively
associated with chronic lung injury (225). An important phenomenon that promotes
adenosine accumulation is purinergic remodeling, a phenomenon characterized by
increased expression of the ectonucleotidase CD73 and reduced ADA and ENTs that
collectively promote extracellular adenosine accumulation and subsequent ADORA2B
activation (246). This phenomenon has been shown to be present in chronic lung
diseases such as COPD and IPF (247), and my data from CPFE explanted lung tissue
reveals evidence of purinergic remodeling consistent with increased ADORA2B
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expression. Taken together, these observations advocate the use of an ADORA2B
antagonist to treat chronic lung diseases. Indeed, preclinical studies using both Ada-/and bleomycin-treated mice have demonstrated that genetic or pharmacological
abrogation of Adora2b signaling is capable of attenuating features of chronic lung injury
(158, 190, 239, 248).
Unexpectedly, treatment with 4MU was not able to attenuate airspace
enlargement, RVH or metabolic changes in Ada-/- mice. RVH is typically a response to
increased RVSP, as such it is conceivable for changes to be observed over time following
normalization of blood pressure. Airspace enlargement may however be due to other
adenosinergic mechanisms promoting alveolar cell destruction. These potential
mechanisms may include elevations in deoxy-adenosine a molecule that is also
metabolized by ADA and accumulates in Ada-/- mice (249). Increased phosphorylation
of deoxy-adenosine by deoxy-cytosine kinase has been shown to contribute to airspace
enlargement in Ada-/- mice and increased deoxy-cytosine kinase signals have been
detected in stage 4 COPD (249). Taken together, these studies suggest that treatment
of 4MU may not alter deoxy-cytosine kinase or deoxy-adenosine levels to alter airspace
enlargement. Similarly, alterations in metabolism have also been reported in Ada-/- mice
(237) that may not be affected by 4MU, but this compound may be effective at treating
lung fibrosis and PH in CPFE.
In conclusion, my study has demonstrated that a gradual reduction of PEG-ADA
to male 6-month-old Ada-/- mice results in the development of hallmarks of CPFE:
airspace enlargement, fibrotic deposition and PH. In addition, I demonstrate using a
therapeutic approach that the FDA-approved drug, 4MU, is capable of reducing the
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extent of fibrotic injury and features of PH. My study also proposes a novel mechanism
whereby Has3-positive macrophages contribute to chronic lung injury in Ada-/- mice.
Importantly, observations in the experimental model of CPFE were recapitulated in lung
explants from patients with CPFE, where increased hyaluronan was detected in
remodeled areas of the lung consistent with HAS3 expressing CD68-positive cells. These
results are significant since very little is known regarding the mechanisms that promote
injury in CPFE and as a result limited therapies exist for this deadly condition. My study
proposes that inhibition of hyaluronan accumulation is as a novel potential therapy for
CPFE.
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Chapter 6: Conclusions and Future Directions
Conclusions
The work presented here contributes to our understanding of the molecular
changes involved in vascular remodeling and PH. My work has identified a role for
NUDT21 in the pathogenesis of PH. Specifically, I demonstrate that NUDT21 depletion
is present in remodeled vessels of patients with either Group 1 or Group 3 PH and that
NUDT21 depleted PASMCs undergo a phenotypic switch that promotes vascular
remodeling. There were also large gaps in the knowledge about the role of HA in
contributing to vascular remodeling in Group 1 or Group 3 PH. While HA and HA
related enzymes had been shown to be associated with PH, the mechanism had not
been fully explored. I describe two pathways through which changes in HA deposition
in the lung contribute to disease.
The results in Chapter 3 describe a novel mechanism for changes in PASMCs
during PH development through regulation of RNA maturation. While NUDT21
mediated APA has been described in several disease states to this point, it has not been
shown in PASMCs or in PH. These changes observed in the PASMCs are consistent with
changes seen in the literature in PH. Interestingly, NUDT21 deletion in PASMCs leads
to increased RVSP in the absence of hypoxia-sugen model. This finding together with
the fact that over-expression of NUDT21 in PASMCs from patients restores them to a
proliferative phenotype similar to cells from healthy donors indicates that NUDT21 is a
key regulator of vascular remodeling and PH. This new mechanism adds to our current
knowledge of the pathways that drive vascular remodeling and PH.
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The results in Chapter 4 describe the role and mechanism of HAS2 in PASMCs.
Here I describe the role of HA in the development of PH, showing that, 4MU, an
inhibitor of HA production, inhibited RVSP in two models of PH. I additionally showed
that deletion of HAS2 from the PASMCs of mice is also protective from PH. While
previous studies have shown an association between increased HA and chronic lung
disease, my research was the first to identify a causative role of HA. This research is also
the first to use pharmacological inhibition of HA production to treat PH. This finding
is exciting in that it identifies a potential therapy for this disease. Not only did I describe
the role of HA in PH, I also identified one of the pathways through which these cellular
changes are produced. Using the Rho-kinase inhibitor fasudil allowed me to describe
the RhoA/ROCK signaling pathway as the signaling pathway through which HA signals
in these cells.
The results in Chapter 5 describe the role of HA in CPFE, a relatively recently
defined disease. As a recently classified disease, few mechanistic studies have been
performed to understand the initiation and development of CPFE. Previous work in the
lab has described the role of ADORA2B in regulating HA production in chronic lung
diseases but did not describe mechanism or look at CPFE. In this work I first studied
the ADA deficient mouse and discovered a novel model for CPFE, including the
combined fibrotic deposition and destruction of the alveoli and associate PH. As
ADORA2B expression and HA were upregulated in this model I then were able to
describe the use of 4MU in treatment of the fibrotic deposition and PH symptoms in
this mouse model. This also revealed that the emphysematic portion of this disease may
be caused by adenosinergic signaling but it is not associated with HA. I also describe a
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group of HAS3 expressing macrophages that is found in association with both the mouse
model of CPFE and patient samples of CPFE.
Given the complex cellular interaction in the lung and equally complex
intracellular regulation of pulmonary cells it is difficult to discover the mechanisms that
contribute to chronic lung diseases. Here I describe two mechanisms involved in the
progression of PH and one of the first mechanisms described for the progression of
CPFE. This advance in knowledge is important in the continued struggle to understand
these chronic and progressive diseases, and will provide novel opportunities for
continued research and therapeutic research.

Future Directions
NUDT21 in other chronic lung diseases
The most direct next step that is indicated by the research here as well and previously
published studies is to identify the role of NUDT21 depletion in other chronic lung
diseases. One of the first to be investigated should be CPFE. The role of NUDT21
mediated APA has been shown in fibroblast in IPF and this thesis has shown this process
is important in PH. Additionally, preliminary data here shows NUDT21 depletion in
COPD lung tissue (Figure 33). Taken together, these data strongly support a role for this
mechanism in the pathogenesis of CPFE as it is important in key malignant processes,
fibrosis and emphysema, as well as the often-associated PH.
To characterize the role of NUDT21 mediated APA in CPFE a two-pronged
approach should be taken. Human CPFE tissue should be analyzed for NUDT21 changes
by western blot, and then RT-PCR should be utilized to test for APA events in the genes
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most well characterized to shorten such as VMA21. At the same time tissue from the
ADA deficient mouse model of CPFE should be analyzed in the same manner.
To identify the APA targets important to this disease, it is likely that analysis of
whole tissue will be confounded by APA events that differ between cell types. To
mitigate this, cells should be isolated from either patients or the mouse model and
then analyzed for APA changes against healthy controls. The cell types to be analyzed
should be fibroblasts, PASMCs, and alveolar epithelial type 2 cells which undergo
apoptosis in COPD (250). Identifying this mechanism as important in CPFE would add
additional knowledge to this poorly understood and complex disease.

Figure 33 Reduced NUDT21 Levels in COPD
Western blot for NUDT21 and GAPDH in Normal and COPD patient lung samples.

What other genes are shortened by NUDT21 depletion in PH.
As discussed in Chapter 1 several key changes happen to PASMCs during vascular
remodeling. My results show that NUDT21 depletion plays a role in modulating the
proliferative and migratory capacity of PASMCs. While shortening and increased
expression of HAS2 mRNA plays a role in this change, other genes are also involved.
The DaPars algorithm identified 664 shortened genes in the NUDT21 knock down in
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PASMCs. The data from this algorithm identified RUNX1 as one of the most shortened
targets of NUDT21 depletion. This shortening was also associated with increased reads
indicating increased mRNA levels. RUNX1 is a poorly described transcription factor
known to be expressed in hematopoietic stems cells and plays an important role in
controlling proliferation and self-renewal (251). Additionally mutations in this gene
contribute to a wide variety of leukemia types (252). RUNX2 along with a common
cofactor with RUNX1, CBFβ, has been implicated in proliferation of PASMCs and
remodeling in PH (253). As shortening of RUNX1 lead to aberrant expression in the
NUDT21 knock down, and RUNX1 is a strong driver of disease states, investigating the
role of this shortening in PH is encouraging.
To identify if RUNX1 3’UTR shortening is an important downstream effect of NUDT21
depletion several studies need to be performed. First RUNX1 shortening in PAH patient
samples should be confirmed by DaPars analysis of RNA-seq data. This should also be
determined by RT-PCR experiments to show dPAS usage. After this APA event has been
confirmed in human samples of disease, a mechanistic link should be determined. In
vitro it should be shown that RUNX1 is necessary for NUDT21 mediated changes in
PASMCs phenotype by knocking down NUDT21 with siRNA and then treating the cells
with 2-pyridyl benzimidazole AI-4-57, a RUNX1-CFBβ inhibitor. If the phenotype of
these cells differs from controls with only NUDT21 a mechanistic link will be confirmed.
In the event that inhibitor is toxic to these cells I can use siRNA to knockdown RUNX1
as well. It will also be confirmed that RUNX1 is shortened in the PASMCs of C57B/6
mice and NUDT21f/+TaglnCre mice in the hypoxia-sugen model. The same inhibitor can
be used to treat these mice to determine if blocking RUNX1 induced by NUDT21
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mediated APA is a therapeutic option in PH. Continued studies could identify
aberrantly expressed genes activated by RUNX1 binding. Identifying the pathways that
lead to proliferation in NUDT21 downregulation will likely identify pathways key for PH
development.

Targeting NUDT21 depletion mediated APA therapeutically.
While NUDT21 depletion appears to be sufficient to induce phenotypic changes in
PASMCs, it is not evident what mechanisms control these levels during the initiation of
PH. In order to target this mechanism therapeutically it is important to know what
regulated NUDT21 levels. It is known that several miRNAs including miRNA-181a target
NUDT21. In fact miRNA181a appears to drive a NUDT21 depletion dependent increase
in proliferation in osteosarcoma (116). To determine if miRNAs control the level of
NUDT21 in PASMCs during PH the transcript sequence of NUDT21 should be analyzed
by a tool such as TargetScanHuman 7.2. The miRNA hits that this tool predicts should
then be cross-referenced against miRNAs known to be induced during PH (254). The
miRNAs in both sets should then be investigated using a dual luciferase vector with the
NUDT21 3’UTR as the target sequence. Identification of one or more miRNAs that are
upregulated in PH and that strongly downregulate NUDT21 in this assay would provide
strong evidence that this is the mechanism of control. It is also possible that other
pathways contribute to changes in NUDT21 levels. Investigating the transcription
factors and enhancers that activate NUDT21 expression would require more in-depth
studies but could provide interesting insights.
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An additional area of potential therapeutics is the CFIm complex as a whole. My
research focused on the role of NUDT21 on PH but I did show reduced levels of CFIm59
and CFIm68 in several disease states. These decreases were not as consistent as with
NUDT21 but could be as important for some roles of CFIm. As discussed previously
NUDT21 likely acts in concert with its partners by binding two of the same protein in
quaternary complex (255). If these other partners provide some specificity in controlling
cleavage and polyadenylation, it is possible that targeting only one of CFIm59 or
CFIm68 would provide more targeted changes in PASMCs without effecting APA in
such a global scale, which may have unintended effects. To investigate this, PASMCs in
culture should be depleted of either CFIm59 or CFIm68 and then proliferative and
migratory outcomes can be observed. If these changes are similar to that seen in
NUDT21 depletion, then a study of the APA landscape can begin, first with RT-PCR of
known regulators seen in the NUDT21 studies and eventually with RNA-seq to
understand how the APA landscape differs. The eventual goal would be to identify a
target interaction key to PH associated APA but not necessary for steady state cleavage
and polyadenylation that could be used as a target to screen compounds that would
simply interrupt that one interaction.

4MU as a therapy for PH in patients
Undoubtedly the most significant and daunting next steps implicated by the findings
here is that of testing 4MU in patients with PH. 4MU is an approved therapy for biliary
dyskinesia in some countries under the name hymecromone. In the clinical trials for
this use no severe side effects were seen and treatment by oral delivery is effective.
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Unfortunately the pharmacology is not ideal for treatments, as 4MU is quickly
metabolized and excreted from the body (256). This drug has also not been tested in a
chronic treatment scenario with on label usage only for acute biliary spasms and a single
trial showing relative safety for three months of treatment (257). Despite this, my
findings support using this drug for patients with PH. This drug is also a potential target
for cancer research as in vitro studies have shown that 4-MU treatment reduces cancer
metastasis (258). In a mouse model with implanted cancer cells, 4MU treatment
reduced tumor size (259). As there is no curative treatment and PH is progressive any
treatment that could provide distinct benefits should be investigated, especially one
with few side effects that has been used to treat other disease.
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Appendix: Materials and Methods

Scientific Rigor
All analyses were blinded to the experimenter. A two-way analysis of variance (ANOVA)
with the Bonferroni correction was performed for all experiments with more than 2
groups. For experiments that consisted of two groups, an un-paired two-tailed Students
t-test. The Grubbs' test was used to detect outliers. GraphPad Prism 7.0 or higher was
used to analyze the data. All software used in this study is available commercially.
Sex as a biological variable
In experiments using IP BLM, male mice were utilized, as IPF is more prevalent in males
than in females (260-262). Male mice also have a greater response to BLM than female
mice irrespective of age (263). In the hypoxia-sugen model both male and female mice
are used and no difference in symptoms or histology is observed. As CPFE is ~20 times
more prevalent in males than females, the chronic ADA deficient mouse model utilizes
only males of six months of age (264).
As IPF is much more prevalent in males, male patients dominated the samples of this
diagnosis though a more even sex distribution is available for patients with IPF+PH.
PAH is 2-4 times more prevalent is females and this is evident in the available samples
(5). CPFE patient samples were only collected from males as the disease is almost
exclusively male and the disease was only recently described. As healthy lungs are
typically only explanted for potential transplantation, it is uncommon to receive healthy
tissue from age matched controls.
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Human subjects
The use of human material for this study was reviewed by the University of Texas Health
Science Center at Houston Committee for the Protection of Human Subjects
(Institutional Review Board no. HSC-MS-08-0354). The demographic details of the
study population are summarized in Table 1. De-identified lung explant tissue from
patients with IPF and corresponding de-identified clinical parameters were obtained
from the Methodist Hospital (Houston, TX). IPF was diagnosed by board-certified
pulmonologists upon admittance for lung transplantation at the Houston Methodist
Hospital. Pulmonary hypertension was defined as a mean pulmonary pressure ≥ 25
mmHg and a pulmonary capillary wedge pressure ≤ 15 mmHg; the hemodynamic
measurements were obtained from the right heart catheterization performed as part of
the transplant evaluation. Control lung tissue was obtained from lungs that were
declined for transplantation but had no pulmonary chronic disease or contusion.
Healthy control lung tissue was obtained from the International Institute for the
Advancement of Medicine (Edison, NJ).
Tissue was collected at the time of lung explantation and processed on site within 20
min. The lobes were identified from each lung explant, and for each lobe, the center was
identified, taking the airway as a reference point. A 1 cm transverse center cut was
performed to obtain a section from the center of each lobe. Consequently, this tissue
was divided into three sections to separate external (closest to pleura), center and
internal (closest to bronchi) portion according to the airway. A piece from each portion
was then cut for histology, and an adjacent section was flash frozen in liquid nitrogen.
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IPF (n=10) IPF + PH(n=9)
Female 2/10
4/9
Males
8/10
5/9
Age
63.4±2.9
57.3±4.6
mPAP
20.0±1.7
31.3±1.5
BMI
27.9±1.7
30.0±1.8
Table 1 Human Subjects

PAH(n=6)
5/6
1/6
47.5±13.1
48±9.6
25.5±5.5

CPFE(n=4)
0/4
4/4
60.4±7.0
24±4.5
28.0±1.0

Healthy(n=8)
5/10
5/10
41.1±14.3
Not Measured
31.3±3.8

Animal subjects
All animal care and experimental studies were reviewed and approved by the University
of Texas Health Science Center at Houston Animal Welfare Committee Animal studies
are reported in compliance with the ARRIVE (Kilkenny et al., 2010; McGrath and Lilley,
2015), institutional and NIH guidelines. Male C57/BL6 mice 4–5 weeks old weighing 20–
22 g were purchased from Envigo Industries (Indianapolis, IN, USA). All mice were
housed in ventilated cages equipped with microisolator lids and maintained under strict
containment protocols. Mice were housed 5 per cage and were provided with variable
free paper bedding (Pure-o'Cel The Andersons, Inc. Maumee, OH, USA) and Nestlets™
provided by Ancare (Bellmore, NY, USA). Mice were kept at an ambient temperature of
22°C and in a 12 h dark/light cycle.

Hypoxia-sugen
Mice were kept in a naturally ventilated cage inside a chamber with positive pressure
(A-Chamber, Biospherix, Lacona, NY) and exposes to 10% oxygen by addition of
displacing nitrogen for 28 days. Oxygen levels were monitored and controlled by an
oxygen regulator from OKO Labs (Pozzuoli, NA, Italy). Once weekly 20mg/kg of
SUGEN (SU5416; Tocirs, Bristol, United Kingdom) was injected intra-peritoneal after
dissolving in 10% Kolliphor HS 15(Sigma Aldrich, St Louis, MO). Control mice were
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maintained in room air in the same room. Hemodynamic measures of the mice were
made at day 28 and samples harvested after they were euthanized.

Bleomycin
Mice were treated with 0.035 Ug−1 of bleomycin (TEVA Pharmaceuticals, Sellersville,
PA, USA) or vehicle (PBS; Life Technologies, Grand Island, NY) twice a week for 4 weeks
i.p On day 15, mice were provided with chow containing 4-MU (Sigma Aldrich, Saint
Louis, MO, USA), at a dose of 20 mg·kg−1 per day or normal chow (vehicle, Teklad,
Industries, Indianapolis, IN, USA) for the remainder of the experiment. To deliver 20
mg·kg−1 per day 4MU was added to the diet at a concentration of 125 mg·kg−1 diet
(assuming mean body weight ~25 g and intake ~4 g·per day). This was calculated by a
Nutritionist at Harlan Laboratories (now Envigo). On day 33, physiological readouts
were performed and the animals were then sacrificed for the collection of tissues and
fluids for analysis. Mice were assessed bi-weekly for changes in body weight, lack of
grooming or hunched posture by lab personnel and once-weekly by veterinarians at our
facility. In a separate cohort of experiments, 4MU therapy (or control chow) began on
day 33 of BLM exposure and lasted for 14 days. Physiological readouts and tissue
collection were performed on day 47.

NUDT21 KO Mice
NUDT21F/F mice were crossed with TaglnCreKI (Taglntm2(cre)Yec/J Jackson Laboratory)
mice. These NUDT21F/- were used as the experimental group with TaglnCreKI as the
control group. Mice were age matched.
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ADA mice
To generate Ada-/- postnatal mice, an ADA minigene that targeted expression
specifically to the trophoblast lineage was introduced onto the Ada-/- background. This
was accomplished by intercrossing mice carrying the trophoblast-specific ADA
minigene (Tg) with mice heterozygous for the null Ada allele (m1/+). Subsequent
intercrosses yielded litters that contained mice harboring the ADA minigene (Tg) that
were also homozygous for the nullAda allele (m1/m1). Given that the regulatory
elements used targeted Ada expression only to trophoblasts, once born, and with the
loss of the placenta, Tg-m1/m1 mice lacked ADA enzymatic activity. Mice homozygous
for the Ada-null allele were designated Ada−/−, while control mice, designated Ada+,
were heterozygous for the Ada-null allele. Ada−/− and Ada+ mice were congenic on a
C57BLk/6J background. Male 24-week-old Ada-/- mice or littermate Ada+ controls were
used for all experiments.
Ada−/− mice were identified at birth and maintained on ADA enzyme therapy from
postnatal day (PD) 2 until postnatal day 25 as follows: PD5: 1.25 UI IM, PD9-PD17: 2.5
UI IM, PD21: 2.5 UI IP, PD25: 5 UI IP. Starting on PD25 mice received weekly doses of
PEG-ADA (5UI IP) until PD168 (week 24). Mice were randomized to group treatment
using a random number generator using www.graphpad.com/quickcalcs. Starting on
week 24, PEG-ADA was gradually reduced over the course of 9 weeks to 0.125 UI IP as
follows: week 1: 5UI IP, week 2: 2.5UI IP, week 3 and 4: 1.25UI IP, week 5 and 6: 0.625UI
IP, week 7 and 8: 0.312 UI IP, week 9: 0.125UI IP. On week 34 mice were provided with
medicated chow containing 4-Methylumbelliferone (4MU; Sigma Aldrich, Saint Louis,
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MO) also known as hymecromone at a dose of 20 mg kg-1 body weight (BW) per day-1
or normal chow (vehicle, Teklad, Industries, Indianapolis, IN) for 4 weeks. During the
course of these 4 weeks, mice were kept at 0.0125 UI IP of PEG-ADA. On PD 266 (week
38) physiological readouts were performed and the animals were then sacrificed for the
collection of tissues and fluids for analysis (details below).

Arterial oxygen saturation
Physiological assessment measuring arterial oxygen saturation was conducted on
conscious mice using the pulse MouseOx software analysis (STARR Life Sciences Corp,
Oakmont, PA). The hair around the neck was removed from mice in order to use the
collar clip light sensor. The MouseOx provides real-time percent oxygen saturation of
functional arterial hemoglobin by utilizing pulse oximetry measurements of light
absorption from the red and infrared LEDs (Light Emitting Diodes).

Hemodynamic measurements
Right ventricle systolic pressure (RVSP); heart rate and right ventricle (RV)
hypertrophy. Mice are given 0.75 mg g−1of 5% Avertin (a mixture of tert-amyl alcohol
and 2–2-2 tribromoethanol, Sigma Aldrich) to induce a surgical plane of anesthesia.
Mice are placed on a heated surgical workstation (Molecular Imaging Products, Bend,
OR) and secured with surgical tape. Mice were then tracheotomized with a 19G blunt
needle (BRICO, Dayton, NJ) and attached to a small animal ventilator (MiniVent, HugoSachs Elektronik, March-Hugstetten, Germany) and ventilated at a stroke volume of
250 μL at 200 strokes per minute. The surgical site was viewed using a surgical
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microscope (SMZ-2B, Nikon, Tokyo, Japan). An incision of ∼1 cm in length was made
just below the xiphoid process. An alm retractor (ALM-112, Braintree Scientific,
Braintree, MA) was used to expose the abdominal cavity to visualize the diaphragm and
the liver. An incision was then made on the diaphragm to expose the heart and the
pericardium then removed. The right ventricle was then identified and a puncture made
with a 28G needle. A 1 French pressure catheter (SPR-1000, Millar Instruments,
Houston, TX) was then inserted through the puncture. Using the same procedure, I
recorded LVSP, immediately after RVSP measurements. The heart rate results were
continuously recorded using a Powerlab 8-SP A/D (AD Instruments) converter,
acquired at 1000 Hz. All RVSP results were recorder to a PC utilizing Chart8 software.
After completion of the measurements, blood was collected and the lungs were excised
and flash frozen in liquid nitrogen for RNA extraction. The heart was excised and the
atria were removed. The right ventricle was then surgically removed and the dry weights
of the RV were used to determine the extent of RV-hypertrophy (RV/left ventricle [LV]
+ septum). A heart rate below 250 beats per minute (BPM) during the determination of
the RVSP or LVSP was considered as a violation of a predetermined criteria.

RT-PCR
Total RNA was isolated from frozen lung tissue using Trizol reagent (Life Technologies).
RNA samples were then DNase treated (ArticZymes, Tromso, Norway) and subjected to
quantitative real-time RT-PCR. Here two technical replicates were performed per
sample. Prior to RT-PCR experiments RNA quality was evaluated using a Nanodrop
(Thermo Fisher Scientific, Waltham, MA, USA); to evaluate 260 nm / 280 nm
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absorbance values. Samples with 260/280 absorbance rations below 1.90 or above 2.10
were considered to have poor RNA quality and thus violated a predetermined criterion.
Gene

Forward

Reverse

18SrRNA

GTAACCCGTTGAACCCCATT

CCATCCAATCGGTAGTAGCG

hADA
hADORA1A
hADORA2A

GGGCTGCTGAACGTCATTG
TGCACTGACTTCTACGGCTG
CGCTCCGGTACAATGGCTT

AGGCATGTAGTAGTCAAACTTGG
GGTCCCCGTGACCAAACTT
TTGTTCCAACCTAGCATGGGA

hADORA2B
hADORA3
hCD39

TGCACTGACTTCTACGGCTG
TCATTCTACTCTCCTTGGCTCTC
AGGTGCCTATGGCTGGATTAC

GGTCCCCGTGACCAAACTT
GTGGGCATTGTAGTTGCAGAT
CCAAAGCTCCAAAGGTTTCCT

hCD44

AGAAGGTGTGGGCAGAAGAA

AAATGCACCATTTCCTGAGA

hCD73

CCAGTACCAGGGCACTATCTG

TGGCTCGATCAGTCCTTCCA

hCOL1A1

GTGCGATGACGTGATCTGTGA

CGGTGGTTTCTTGGTCGGT

hCOL1A2

GAGCGGTAACAAGGGTGAGC

CTTCCCCATTAGGGCCTCTC

hCOL2A1

TGGACGCCATGAAGGTTTTCT

TGGGAGCCAGATTGTCATCTC

hENT2

GGGGTACTTTATCACGCCCTG

GGGAATCCCGTTCTCATCAGA

hFN1

GGTGGAATAGAGCTCCCAGG

GCAGCCTGCATCTGAGTACA

hHAS1

GAGCCTCTTCGCGTACCTG

CCTCCTGGTAGGCGGAGAT

hHAS1

GAGCCTCTTCGCGTACCTG

CCTCCTGGTAGGCGGAGAT

hHAS2

TCCTGGATCTCATTCCTCAGC

TGCACTGAACACACCCAAAATA

hHAS2

TCCAAAGAGTGTGGTTCCAA

GACAGGCTGAGGACGACTTT

hHAS2Distal

CTGGCAGTGTTTTCCCAGAAC

CAGGCCACAGAACAAAACCT

hHAS2Total

TCCCGCTGAGACAGATGAGT

CAGTGCTCTGAAGGCTGTGT

hHAS3

CGCAGCAACTTCCATGAGG

AGTCGCACACCTGGATGTAGT

hHAS3

CGCAGCAACTTCCATGAGG

AGTCGCACACCTGGATGTAGT

hHPRT1

TGACCTTGATTTATTTTGCATACC

CGAGCAAGACGTTCAGTCCT

hHYAL2

CACGGGGCTTAGTGAGATG

GTCACCCCAGAGGATGACAC

hIL6

AATTCGGTACATCCTCGACGG

TTGGAAGGTTCAGGTTGTTTTCT

hNRF2

ACACGGTCCACAGCTCATC

GCCTCCAAAGTATGTCAATCAA

hSDHA

mADORA2b

GAGGCAGGGTTTAATACAGCA
CATCTGCACAGCACCTTACAGTT
TGC
GATAAGGCGGCGCTGAACGCACT
GC
GCGTCCCGCTCAGGTATAAAG

CCAGTTGTCCTCCTCCATGT
GAAATGCAGCACATCCAAATCCTC
CC
TGAGCCTTCATTCCAGGCCACATAC
ACA
CGGAGTCAATCCAATGCCAAAG

mFN

ACTGGATGGGGTGGGAAT

GGAGTGGCACTGTCAACCTC

mHAS1

GCGAGCACTCACGATCATCTT

GTCCATAGCGATCTGAAGCCA

mHAS2

ACAGATGAGGCAGGGTCAAG

TGGGGTGGAAAGAGAGAAGT

mHYAL1

CCTCAACCCTGCCAGTTTCTC

CCCGCTTGTCACACCACTT

mHyal2

GCAGGACTAGGTCCCATCATC

TTCCATGCTACCACAAAGGGT

mHYAL3

TCTGTGGTATGGAATGTACCCT

TTTTGGCCGTGAAAATGTTGG

hVMA21Distal
hVMA21Total
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mPPARG

GGAAGACCACTCGCATTCCTT

GTAATCAGCAACCATTGGGTCA

mSDHA

GGAACACTCCAAAAACAGACCT

CCACCACTGGGTATTGAGTAGAA

Table 2 RT-PCR Primers

Mouse RT-PCR from Prime PCR plates BioRad(Hercules, CA).
Gene
Unique Assay ID
Actb
qMmuCED0027505
CD44
qMmuCEP0062158
COL1A1 qMmuCID0021007
COL1A2 qMmuCID0021177
COL3A1 qMmuCID0006332
FN1
qMmuCID0019534
HAS1
qMmuCIP0036412
HAS2
qMmuCID0011459
HAS3
qMmuCID0014012
HYAL1
qMmuCEP0042433
HYAL2 qMmuCEP0052809
NRF2
qMmuCIP0033901
TBP
qMmuCID0040542
Table 3 BioRad Primers

Immunoblots and ELISA
For immunoblots protein from lung tissue lysates or PASMC was extracted with RIPA
buffer (Thermo Scientific, Rockford, IL) containing 1 mM of protease and phosphatase
inhibitor (Sigma Aldrich). Samples (30 μg protein each) were loaded onto 4–12% MiniProtean TGX gels (Bio-Rad, Hercules, CA) for electrophoresis and then transferred on
polyvinylidene difluoride (PVDF) membranes (0.45 μm, GE Healthcare Piscataway, NJ).
Membranes were then blocked in 5% milk (Bio-Rad) for 1 h at room temperature and
then incubated with the appropriate primary antibody overnight. Secondary antibodies
and an ECL kit from (GE Healthcare) were applied for generating chemiluminescent
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signals. Blots imaged with the ChemiDoc Touch (Bio-Rad) using optimal auto exposure
settings. Quantification of these blots were carried out with the Image Lab Software
(Bio-Rad) to quantify densitometry as well as intensity of target bands and control
bands. The expression was then calculated relative to control band and output in
arbitrary units.
BALF was extracted by flushing the lungs with 0.5 mL of cold PBS twice and collecting
the fluid using a 1 mL syringe. The presence of blood in BALF was considered as a
violation of pre-established criteria. Hyaluronan levels in BALF were measured by
ELISA using a kit from Echelon Biosciences (Salt Lake City, UT), with two technical
replicates per sample.

Histology and immunohistochemistry (IHC)
Lung sections 5 microns thick, were dewaxed using histoclear (National Diagnostics,
Atlanta, GA) and re-hydrated using a gradient of ethanol. Sections were then subject to
high temperature antigen retrieval using a citrate buffer, endogenous peroxidase and
alkaline phosphatase were inactivated using BLOXALL (Vector Labs, Burlingame, CA)
and 2.5% normal horse serum (Vector Labs) was using as a blocking solution prior to
incubation with the primary antibody. Following overnight incubation with the primary
antibody, sections were treated with the ImmPRESS polymer detection kits for alkaline
phosphatase (Vector Labs) based on the host of the primary antibody and developed
using Vector red or Vector Blue (Vector Labs). For immunofluorescence chicken antimouse Alexa Fluor 488 (Life Technologies Carlsbad, CA) was used and counterstained
DAPI (Abcam). Lungs stained with Massons's Tri-chrome were analyzed using a
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modified Ashcroft scale optimized for mouse lung sections. To detect hyaluronic acid,
sections were incubated with 4 µg/ml of biotinylated HA-binding protein (HABP,
Calbiochem, 1:125 Darmstadt, Germany) overnight at 4°C, incubated with the ABC kit
and developed with Vector Blue. For immunofluorescence, sections were incubated
with SMA and incubated with Alexa Fluor 488 or Alexa Fluor 555 (1:500, Sigma-Aldrich,
St Louis, MO) sections were counterstained and mounted with DAPI or PI mounting
media (Sigma-Aldrich, St Louis, MO).

Concentration
1:1000
1:1000
1:100
1:1000
1:1000
1:500
1:1000
1:1000
1:200

Antibody
αSMA
CD44
CD68
CFIm59
CFIm68
F4/80
GAPDH
GEFT(Human)
GEFT(Mouse)

Company
Sigma-Aldrich (clone 1a1)
Fitzgerald 10R-2062
Abcam ab125212
Proteintech
Proteintech 15489-1-AP
Biorad MCA497
Thermo Fisher AM4300
GeneTex GTX121237
Santa Cruz sc-16137

HABP2

Has2

Thermo Fisher PA5-25573 1:100
1:500 IB
Thermo Fisher PA550674
1:100 IHC
1:200
Abbexa abx10958

Has3

Santa Cruz sc-365322

1:1000

Hyal1

Santa Cruz sc-1101340

1:200

Hyal2

Santa Cruz sc-99022

1:200

NUDT21

Proteintech 10322-1-AP

1:1000

Has1

β-actin
Sigma A5316
Table 4 Antibodies
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1:1000

Morphometry
Muscularized arterioles of the lung parenchyma were observed under 40× magnification
and noted as being different from both airways and non-muscularized arterioles.
Muscularized

arterioles

Micropictographs

were

were
then

then

photographed

analyzed

using

under
Image

40×

magnification.

Pro-Plus

software

(MediaCybernetics Inc, Bethesda, MD). In short, the overall area of the muscularized
portion was measured for each arteriole. To correct for size, the largest diameter for
each arteriole was also measured. The area of the arteriole was then divided by the
largest diameter to give a relative measurement of muscularization. Poor inflation of
lungs resulting in a compression of airspaces visualized histologically in normal areas
of the lung by an observer blinded to group status was considered as a violation of
predetermined criteria.
To quantify airspace enlargement, alveolar air-space size was determined in pressure
infused lungs by measuring mean chord lengths on H&E-stained lung sections.
Representative images (black and white) were digitized, and a grid consisting of 53 black
lines at 10.5 µm intervals was overlaid on each image. This line grid was subtracted from
the black and white lung images using Image-Pro Plus image analysis software (version
2.0; MediaCybernetics). The resultant lines were measured (in µm) and averaged to give
the mean chord length of the airspace enlargement. The final mean chord lengths
represent averages from 10 non-overlapping images of each lung specimen. All
quantitative studies were performed blinded with regard to animal genotype and
treatment. It is important to mention that for the quantification of airspace
enlargement, the images taken were from the parenchyma, devoid of large airway,
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vascular structures or fibrotic deposition. The exclusion of these structures is necessary
to quantify airspace enlargement. However, these exclusions were not performed for
the determination of Ashcroft scores.

RNA-seq
PASMCs(Lonza) were lysed using TRIzol(Life Technologies) and total RNA purified
using the RNeasy Kit(QIAGEN). Total RNA-seq was performed with MiSeq(LC
Sciences). RNA-seq reads were aligned to the human genome(hg19) using TopHat 2.1.1.
3’UTR APA events between control and NUDT21 siRNA treated cells were identified
using the DaPars algorithm. This algorithm identifies de novo APA events through the
use of linear regression models to identify proximal polyadenylation sites and then
estimates the short and long isoform expression levels using read density upstream and
downstream of this calculated polyadenylation site (169). Genes with an absolute
difference of mean PDUIs of no less than 0.1 were identified as having shifted 3′-UTR
events. Pathway analysis was performed using the ConsensusPathDB-human overrepresentation gene set analysis to identify biological networks and functional pathways
enriched in the dataset.

Liquid Chromatography Tandem Mass Spectrometry
4-Methylumbelliferone-[13C4] (Toronto Research Chemicals, Ontario, Canada) and 7hydroxy coumarin β-D-glucuronide (as sodium salt) (Toronto Research Chemicals,
Ontario, Canada) were used as the internal standard (IS) for 4MU and 4MUG
respectively. The stock solutions of a mixture of 4-MU and 4-MUG were diluted in 50%
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methanol to prepare the spiking solutions ranging from 1 ng mL-1 to 5000 ng mL-1. For
calibration standards, 25 μL of blank plasma was mixed with 25 μL of the spiking
solutions. For unknown samples, 25 μL of test plasma was mixed with 25 μL of 50%
methanol to make up the volume. 25 μL of a mixture of the two IS (1000 ng mL-1 in 50%
methanol) was also added. After vortexing all standards and samples, 150 μL of
methanol/acetonitrile 20:80 (v/v) was added to the mixture which was further vortexed
vigorously for 1 min followed by centrifugation at 850 × g for 10 min. 100 μL of the
supernatant was diluted with 200 μL of Milli Q water.
The LC–MS/MS system consists of an AB SCIEX QTRAP 4000 mass spectrometer
coupled to a Shimadzu UFLC system. Mobile phase A is HPLC grade water. Mobile
phase B is HPLC grade acetonitrile. LC separation was carried out on a Phenomenex
Luna PFP(2) column (3 μm, 150 × 2 mm) with isocratic elution using 45% mobile phase
B and a flow rate of 0.4 mL min-1 at room temperature. The analysis time was 2.5 min.
5 μL of the extracted sample was injected. The mass spectrometer was operated in the
negative mode with multiple-reaction monitoring (MRM). The following MRM
transitions were used: 4MU (m/z 174.7 → 132.9), IS for 4MU (m/z 178.7 → 134.9), 4MUG
(m/z 350.8 → 174.9) and IS for 4MUG (m/z 336.9 → 160.9). Data acquisition and analysis
were performed using the Analyst 1.6.1 software (AB SCIEX).

Hyaluronan fragment size assessment
Lung samples from mice were pulverized and suspended in water. Protease (Pronase
Calbiochem #537088) was added to a final concentration of 200u mL-1. This was
digested for 12 h at 55°C. This digestion was repeated six times. Samples were
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centrifuged at 2400 × g for 10 min. The supernatant was concentrated using Corning
Spin-X UF concentrators (CLS431477). Samples were mixed with 4 μL 2 M sucrose and
were run in 0.5% agarose gel in TAE buffer. Hyaluronan size standards were also mixed
with sucrose. Gel was stained with 0.005% Stains-All (Sigma #E-7762) and then
destained in water for 48 h. Images were obtained with the BioRad ChemiDoc Touch.

Cell culture experiments and AFM
Normal control primary PASMC obtained from Dr. Morrell's group (Cambridge, UK)
were cultured in DMEM with or without 100 μM fasudil (R&D Systems). For studies
performed to evaluate the proliferative effect and cyotoxcity of hyaluronan and fasudil,
cells were treated with high molecular weight (HMW; 1350 kDa GLR002 R&D systems,
Minneapolis, MN), medium molecular weight (MMW, 289 kDa GLR004 R&D systems),
low molecular weight (LMW, 20 kDa, GLR001) or ultra-low molecular weight (ULMW,
4.8 kDa GLR003) hyaluronan with or without fasudil (100 μM,). Cell proliferation and
cytotoxicity was determined using the ApoTox-Glo™ Triplex Assay (Promega, Madison
WI). This method relies on measuring two protease activities: one for cell viability and
the other as a marker of cell cytotoxicity. The final part of the assay is the measurement
of a luminogenic substrate for caspase 3/7. For AFM experiments control and fasudil
were treated with no hyaluronan, 5.7 mg of medium molecular weight (MMW)
hyaluronan (R&D Systems GLR004), or 5.7 mg of ULMW hyaluronan (R&D Systems
GLR003). After 24 h the cells were used for AFM measurements at room temperature.
The force curves measurements were performed with a Catalyst Bioscope System
(Bruker Corporation, Billerica, MA). The AFM was equipped with an inverted light
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microscope (Olympus IX81) so that the cells were constantly monitored. Silicon nitride
cantilevers (Novascan Technologies, Inc., Ames, IA) with approximate spring constant
values of 0.06 N m−1 were employed in all AFM experimentations. The AFM probe was
purchased from Novascan (the probe has a silicon nitrite cantilever with a 5μm silica
spherical particle on the end) with a spring constant of 0.06 N s−1. The cantilever
sensitivity was calibrated with the NanoScope 9.0 software by measuring a force curve
on a clean silicon wafer. Force curves were acquired at a sampling rate of 1 Hz. The
Young's modulus, E, was calculated from obtained force curves based on the Hertzian
fit mode using Nanoscope analysis program from the Bruker Corporation. F =
2πE1−υ2tanαδ2 where F = force, E = Young's modulus, ν = Poisson's ratio (ν = 0.5, in this
study), α = half-angle of the indenter (i.e. tip radius, α = 5000 nm, in this study), and δ
= indentation depth.

Cell culture experiments
The mouse alveolar macrophage cell line MH-S (ATCC, Manassas, VA, USA) was
maintained at 37°C and 5% CO2. MH-S cells were grown in RPMI-1640 supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine and penicillinstreptomycin. For experimental use, MH-S were serum-starved overnight in RPMI-1640
supplemented with 2% FBS, 2 mM L-glutamine and penicillin-streptomycin, followed
by 24h exposure to ADORA2B agonist BAY60-6583 (10 µM, Tocris) with or without the
ADORA2B antagonist GS6201 (100 nM, Tocris). PASMCs were maintained in in similar
conditions with starvation occurring for 48hr coinciding with siRNA or plasmid
transfection. Proliferation assay occurred with 0 or 25mM BB-PDGF while migration
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occurred with no serum gradient at 1% FBS or with a gradient from 1-10% FBS in boyden
chambers with 8um pore size.

PASMC isolation
The pulmonary arteries are dissected out of the tissue. The adventitia is then removed
with forceps. The arteries are bisected longitudinally and then treated with 4mL of
digestion mixture. Digestion mixture is a mixture of 4mL of Collagenase Type
II(2mg/mL) and 75 µL of elastase(125U/µL) for about 2 hours. The cells are then grown
in Smooth Muscle Growth Medium(ScienceCell). Cells are used at passage three or
passage 4.

NUDT21 depletion and overexpression
For NUDT21 overexpression the coding region was cloned into the pCDNA3.1 +C
plasmid. 5µg of plasmid or empty vector was transfected using jetPRIME(Polyplus New
York, NY) into a 80% confluent 10cm twice 24hr separated. Depletion was performed
with siRNAs purchased from Sigma-Aldrich(Human NM_007006 260 MISSION siRNA
4) with the same time points and 500pmoles of siRNA.
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